Catcher Technology Co., Ltd. and Subsidiaries

Consolidated Financial Statements for the First Quarter of 2026 and 2025
Independent Auditors' Review Report

Independent Auditors' Review Report

The Board of Directors and Shareholders
Catcher Technology Co., Ltd.,

Introduction

We have audited the consolidated financial statements of Catcher Technology Co., Ltd. and its subsidiaries (hereafter referred to as the "Group"), which comprise the consolidated balance sheets as of March 31, 2026 and 2025, the consolidated statements of comprehensive income, changes in equity, and cash flows for January 1 to March 31, 2026 and 2025, and the notes to the consolidated financial statements, including a summary of significant accounting policies. The management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope

We conducted our reviews in accordance with TWSRE 2410 "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Standards on Review Engagement. A review of consolidated financial statements consists of making inquiries (primarily to personnel responsible for financial and accounting matters) and applying analytical and other reviewing procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review (please see Other Matters), we are not aware of any material aspects in which the aforementioned consolidated financial statements do not comply with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission, and which therefore do not present fairly the consolidated financial conditions of Catcher Group as at March 31, 2026 and 2025, and the consolidated financial performance and the consolidated cash flows from January 1 to March 31, 2026 and 2025.

Other Matters

Among the Group's investments accounted for using the equity method and included in the consolidated financial statements for the first quarters of 2026 and 2025, the financial reports of certain investees were reviewed by accountants other than our own. Thus, in forming our conclusion on the aforementioned consolidated financial statements, the investment amounts of the aforementioned investees accounted for using the equity method were based on the review reports of other accountants. The carrying amounts of investments accounted for using the equity method as of March 31, 2026 and 2025 were NT$2,084,010 thousand and NT$1,685,190 thousand, respectively, accounting for 0.92% and 0.71% of total consolidated assets. For the periods of January 1 to March 31, 2026 and 2025, the share of comprehensive income from associates and joint ventures accounted for using the equity method amounted to NT$68,774 thousand and NT$67,354 thousand, respectively; these amounts represented 1.56% and 0.95%, respectively, of consolidated total comprehensive income.

Emphasis of Matters

As described in Notes 14 and 29 to the consolidated financial statements, the Group obtained significant influence over United Orthopedic Corporation in the first quarter of 2025. Since the purchase price allocation report was not completed until the first quarter of 2026, the consolidated financial statements for the first quarter of 2025 were retrospectively restated in accordance with the applicable requirements and have been reviewed by us. Our review conclusion was not modified in respect of this matter.

As described in Notes 18 and 29 to the consolidated financial statements, the Group entered into a contract with a non-related party to acquire operating assets in the fourth quarter of 2024. Since the purchase price allocation report was not completed until the fourth quarter of 2025, the consolidated financial statements for the first quarter of 2025 were retrospectively restated in accordance with the applicable requirements and have been reviewed by us. Our review conclusion was not modified in respect of this matter.

As described in Notes 13 and 29 to the consolidated financial statements, the Group obtained control over Pacific Hospital Supply Co., Ltd. in the first quarter of 2025. Since the purchase price allocation report was not completed until the fourth quarter of 2025, the consolidated financial statements for the first quarter of 2025 were retrospectively restated in accordance with the applicable requirements and have been reviewed by us. Our review conclusion was not modified in respect of this matter.

The engagement partners on the audits resulting in this independent auditors' review report are Hung-Ju Liao and Chang-Chun Wu.

Deloitte & Touche
Taipei, Taiwan
Republic of China
May 13, 2026

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally accepted and applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and consolidated financial statements shall prevail.

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
MARCH 31, 2026, DECEMBER 31, 2025, AND MARCH 31, 2025

(In Thousands of New Taiwan Dollars)

	March 31, 2026		December 31, 2025		March 31, 2025 (after restatement)	
Assets	**Amount**	**%**	**Amount**	**%**	**Amount**	**%**
CURRENT ASSETS						
Cash and cash equivalents (Note 6)	$ 16,182,860	7	$ 43,747,619	19	$ 30,367,415	13
Financial assets at FVTPL - current (Note 7)	675,097	-	645,361	-	506,228	-
Financial assets at FVTOCI - current (Note 8)	9,035,133	4	8,453,326	4	6,091,857	3
Financial assets at amortized cost - current (Notes 9 and 34)	75,686,924	34	52,177,096	23	67,700,302	29
Notes receivable (Note 11)	9,632	-	12,275	-	14,748	-
Trade receivables (Notes 11 and 25)	3,469,574	1	4,064,478	2	5,566,034	2
Other receivables (Note 11)	1,763,936	1	1,152,103	-	2,034,784	1
Current tax assets	279,550	-	246,869	-	43,088	-
Inventories (Notes 12 and 35)	3,886,113	2	3,436,696	2	2,496,497	1
Other current assets (Note 19)	502,155	-	436,497	-	354,362	-
Total current assets	111,490,974	49	114,372,320	50	115,175,315	49
NON-CURRENT ASSETS						
Financial assets at FVTPL - non-current (Note 7)	3,224,441	1	3,126,895	1	2,996,045	1
Financial assets at FVTOCI - non-current (Note 8)	83,542,115	37	83,958,350	37	90,970,078	39
Financial assets at amortized cost - non-current (Note 9)	27,768	-	28,102	-	909	-
Investments accounted for using the equity method (Note 14)	5,084,343	2	4,607,026	2	3,961,474	2
Property, plant and equipment (Notes 15 and 35)	14,274,691	6	14,187,150	6	14,820,113	6
Right-of-use assets (Note 16)	1,367,642	1	1,353,488	1	1,400,672	1
Investment properties (Note 17)	1,163,895	1	1,164,329	1	1,344,117	1
Intangible assets (Note 18)	996,835	1	1,014,965	-	1,088,200	-
Goodwill (Note 18)	738,366	-	738,366	-	738,366	-
Deferred tax assets	2,422,300	1	2,262,552	1	2,646,118	1
Net defined benefit assets - non-current (Note 4)	26,123	-	26,368	-	19,994	-
Other non-current assets (Note 19)	1,178,842	1	1,177,709	1	1,035,327	-
Total non-current assets	114,047,361	51	113,645,300	50	121,021,413	51
TOTAL ASSETS	$ 225,538,335	100	$ 228,017,620	100	$ 236,196,728	100
LIABILITIES AND EQUITY						
CURRENT LIABILITIES						
Short-term borrowings (Notes 20 and 34)	$ 66,414,098	30	$ 62,078,414	27	$ 48,112,463	20
Contract liabilities - current (Note 25)	76,434	-	98,695	-	56,774	-
Notes payable (Note 21)	4,300	-	4,378	-	4,231	-
Trade payables (Note 21)	2,093,186	1	2,353,021	1	1,937,498	1
Other payables (Note 22)	3,822,099	2	4,389,060	2	3,940,405	2
Dividends payable	19	-	1,871,007	1	2	-
Current tax liabilities	2,961,779	1	2,864,948	1	3,184,289	1
Lease liabilities - current (Note 16)	22,736	-	24,798	-	30,912	-
Other current liabilities (Note 22)	339,990	-	758,792	1	1,081,420	1
Total current liabilities	75,734,641	34	74,443,113	33	58,347,994	25
NON-CURRENT LIABILITIES						
Deferred tax liabilities	6,685,133	3	6,815,480	3	6,576,155	3
Lease liabilities - non-current (Note 16)	532,916	-	535,092	-	533,856	-
Net defined benefit liabilities - non-current (Note 4)	6,548	-	6,550	-	6,544	-
Other non-current liabilities (Note 22)	22,173	-	22,173	-	15,656	-
Total non-current liabilities	7,246,770	3	7,379,295	3	7,132,211	3
Total liabilities	82,981,411	37	81,822,408	36	65,480,205	28
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY (Note 24)						
Share capital						
Ordinary shares	5,613,691	2	5,921,691	3	6,803,641	3
Capital surplus	14,768,560	7	15,576,725	7	17,879,566	8
Retained earnings						
Legal reserve	24,602,174	11	24,602,174	11	24,083,082	10
Special reserve	14,521,192	6	14,521,192	6	-	-
Unappropriated earnings	83,232,042	37	86,964,568	38	119,482,097	51
Total retained earnings	122,355,408	54	126,087,934	55	143,565,179	61
Other equity	(983,863)	-	(3,854,876)	(2)	5,018,628	2
Treasury shares	(2,587,777)	(1)	(886,617)	-	(6,089,572)	(3)
Total equity attributable to owners of the Company	139,166,019	62	142,844,857	63	167,177,442	71
NON-CONTROLLING INTERESTS (Notes 24 and 29)	3,390,905	1	3,350,355	1	3,539,081	1
Total equity	142,556,924	63	146,195,212	64	170,716,523	72
TOTAL LIABILITIES AND EQUITY	$ 225,538,335	100	$ 228,017,620	100	$ 236,196,728	100

The accompanying notes are an integral part of the consolidated financial statements.

(Refer to the review report of Deloitte & Touche dated May 13, 2026)

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
JANUARY 1 TO MARCH 31, 2026 AND 2025

(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	January 1 to March 31, 2026		January 1 to March 31, 2025 (after restatement)	
	Amount	%	Amount	%
OPERATING REVENUE (Note 25)	$ 3,773,945	100	$ 4,350,288	100
OPERATING COSTS (Notes 12 and 26)	2,686,961	71	2,826,679	65
GROSS PROFIT	1,086,984	29	1,523,609	35
OPERATING EXPENSES (Notes 11 and 26)				
Selling and marketing expenses	107,553	3	70,847	2
General and administrative expenses	350,097	9	326,263	7
Research and development expenses	375,147	10	298,422	7
Expected credit impairment loss	10,759	1	2	-
Total operating expenses	843,556	23	695,534	16
PROFIT FROM OPERATIONS	243,428	6	828,075	19
NON-OPERATING INCOME AND EXPENSES (Notes 14 and 26)				
Interest income	1,697,405	45	2,015,285	46
Other income	11,263	-	12,185	-
Foreign currency exchange gains (losses), net	221,925	6	618,118	14
Other gains (losses), net	(62,392)	(1)	715,318	17
Interest expense	(302,527)	(8)	(246,021)	(5)
Share of profits (losses) from associates accounted for using the equity method	42,389	1	49,671	1
Total non-operating income and expenses	1,608,063	43	3,164,556	73
PROFIT BEFORE INCOME TAX	1,851,491	49	3,992,631	92
INCOME TAX EXPENSE (Notes 4 and 27)	315,957	8	1,025,468	24
CURRENT-PERIOD NET PROFIT	1,535,534	41	2,967,163	68

(Continued)

(Continued from previous page)

	January 1 to March 31, 2026		January 1 to March 31, 2025 (after restatement)	
	Amount	%	Amount	%
OTHER COMPREHENSIVE INCOME (LOSS) (Notes 14 and 24)				
Items that will not be reclassified subsequently to profit or loss:				
Unrealized gain (loss) on investments in equity instruments at fair value through other comprehensive income	$ 693,829	18	($ 456,455)	(10)
Share of other comprehensive income from associates accounted for using the equity method	(537)	-	(301)	-
Items that may be reclassified subsequently to profit or loss:				
Exchange differences from translating the financial statements of foreign operations	3,080,113	82	2,124,588	49
Unrealized gain (loss) on investment in debt instruments at fair value through other comprehensive income	(905,623)	(24)	2,477,831	57
Share of other comprehensive income from associates accounted for using the equity method	7,184	-	10,236	-
Other comprehensive income in the current period	2,874,966	76	4,155,899	96
TOTAL COMPREHENSIVE INCOME	$ 4,410,500	117	$ 7,123,062	164
NET PROFIT ATTRIBUTABLE TO:				
Owners of the Company	$ 1,484,484	39	$ 2,894,936	66
Non-controlling interests	51,050	2	72,227	2
	$ 1,535,534	41	$ 2,967,163	68
TOTAL COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO:				
Owners of the Company	$ 4,359,450	116	$ 7,050,835	162
Non-controlling interests	51,050	1	72,227	2
	$ 4,410,500	117	$ 7,123,062	164
EARNINGS PER SHARE (Note 28)				
Basic	$ 2.63		$ 4.43	
Diluted	2.62		4.42	

The accompanying notes are an integral part of the consolidated financial statements.

(Refer to the review report of Deloitte & Touche dated May 13, 2026)

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
JANUARY 1 TO MARCH 31, 2026 AND 2025

(In Thousands of New Taiwan Dollars)

	Equity Attributable to Owners of the Company											
			Retained Earnings			Other Equity						
	Share Capital	Capital Surplus	Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences from Translating the Financial Statements of Foreign Operations	Unrealized Valuation Gain (Loss) on Financial Assets at FVTOCI	Total	Treasury Shares	Total	Non-Controlling Interests	Total Equity
BALANCE AT JANUARY 1, 2026	$ 5,921,691	$ 15,576,725	$ 24,602,174	$ 14,521,192	$ 86,964,568	$ 1,193,327	($ 5,048,203)	($ 3,854,876)	($ 886,617)	$ 142,844,857	$ 3,350,355	$ 146,195,212
Share of changes in associates recognized using the equity method	-	-	-	-	557	-	-	-	-	557	-	557
Donations from shareholders	-	837	-	-	-	-	-	-	-	837	-	837
Net profit from January 1 to March 31, 2026	-	-	-	-	1,484,484	-	-	-	-	1,484,484	51,050	1,535,534
Other comprehensive income after tax from January 1 to March 31, 2026	-	-	-	-	-	3,087,297	(212,331)	2,874,966	-	2,874,966	-	2,874,966
Total comprehensive income from January 1 to March 31, 2026	-	-	-	-	1,484,484	3,087,297	(212,331)	2,874,966	-	4,359,450	51,050	4,410,500
Gain (loss) from disposal of investments in equity instruments at FVTOCI	-	-	-	-	3,953	-	(3,953)	(3,953)	-	-	-	-
Actual acquisition of partial equity of subsidiaries	-	-	-	-	(9,767)	-	-	-	-	(9,767)	(10,500)	(20,267)
Purchase of treasury shares	-	-	-	-	-	-	-	-	(8,029,915)	(8,029,915)	-	(8,029,915)
Cancellation of treasury shares	(308,000)	(809,002)	-	-	(5,211,753)	-	-	-	6,328,755	-	-	-
Balance at March 31, 2026	$ 5,613,691	$ 14,768,560	$ 24,602,174	$ 14,521,192	$ 83,232,042	$ 4,280,624	($ 5,264,487)	($ 983,863)	($ 2,587,777)	$ 139,166,019	$ 3,390,905	$ 142,556,924
Balance at January 1, 2025	$ 6,803,641	$ 17,878,365	$ 24,083,082	$ -	$ 116,563,726	$ 7,508,967	($ 6,589,128)	$ 919,839	($ 1,672,820)	$ 164,575,833	$ -	$ 164,575,833
Share of changes in associates recognized using the equity method	-	(1)	-	-	267	-	-	-	-	266	-	266
Donations from shareholders	-	1,199	-	-	-	-	-	-	-	1,199	-	1,199
Net profit from January 1 to March 31, 2025 (after restatement)	-	-	-	-	2,894,936	-	-	-	-	2,894,936	72,227	2,967,163
Other comprehensive income after tax from January 1 to March 31, 2025	-	-	-	-	-	2,134,824	2,021,075	4,155,899	-	4,155,899	-	4,155,899
Total comprehensive income from January 1 to March 31, 2025 (after restatement)	-	-	-	-	2,894,936	2,134,824	2,021,075	4,155,899	-	7,050,835	72,227	7,123,062
Changes in capital surplus of subsidiaries	-	3	-	-	-	-	-	-	-	3	7	10
Gain (loss) from disposal of investments in equity instruments at FVTOCI	-	-	-	-	57,110	-	(57,110)	(57,110)	-	-	-	-
Actual acquisition of partial equity of subsidiaries	-	-	-	-	(33,942)	-	-	-	-	(33,942)	(26,211)	(60,153)
Purchase of treasury shares	-	-	-	-	-	-	-	-	(4,416,752)	(4,416,752)	-	(4,416,752)
Increase in non-controlling interests (after restatement)	-	-	-	-	-	-	-	-	-	-	3,493,058	3,493,058
BALANCE AT MARCH 31, 2025 (after restatement)	$ 6,803,641	$ 17,879,566	$ 24,083,082	$ -	$ 119,482,097	$ 9,643,791	($ 4,625,163)	$ 5,018,628	($ 6,089,572)	$ 167,177,442	$ 3,539,081	$ 170,716,523

The accompanying notes are an integral part of the consolidated financial statements.

(Refer to the review report of Deloitte & Touche dated May 13, 2026)

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
JANUARY 1 TO MARCH 31, 2026 AND 2025

(In Thousands of New Taiwan Dollars)

	January 1 to March 31, 2026	January 1 to March 31, 2025 (after restatement)
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before tax	$ 1,851,491	$ 3,992,631
Income and expenses		
Depreciation expense	380,072	390,554
Amortization expense	29,718	31,152
Expected credit loss	10,759	2
Net profit or loss of financial assets measured at fair value through profit or loss	59,202	(49,985)
Interest expense	302,527	246,021
Interest income	(1,697,405)	(2,015,285)
Dividend income	(4)	(5)
Share of (profit) loss of associates accounted for using the equity method	(42,389)	(49,671)
Proceeds from disposal of property, plant and equipment	(81,079)	(158,082)
Net loss on disposal of financial assets	219	9,929
Gains on disposal of investments accounted for using the equity method	-	(480,772)
Inventory write-down and obsolescence loss	3,580	4,359
Unrealized foreign exchange loss	648,665	54,632
Net changes in operating assets and liabilities		
Notes receivable	2,644	(4,483)
Trade receivables	591,051	400,012
Other receivables	9,828	28,572
Inventories	(394,412)	(325,857)
Other current assets	(98,607)	(35,522)
Contract liabilities	(22,261)	(8,000)
Notes payable	(78)	(209)
Trade payables	(312,247)	(462,325)
Other payables	(691,705)	(508,876)
Other current liabilities	(272,503)	97,794
Net defined benefit liabilities	(1)	6
Other operating liabilities	-	10,630
Cash generated from operations	277,065	1,167,222
Dividends received	4	3
Income tax paid	(538,793)	(415,266)
Net cash generated from (used in) operating activities	(261,724)	751,959
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of financial assets at fair value through other comprehensive income	(203,580)	(268,533)
Proceeds from sale of financial assets at fair value through other comprehensive income	1,351,405	85,218
Purchase of financial assets at amortized cost	(72,454,107)	(56,249,528)

(Continued)

(Continued from previous page)

	January 1 to March 31, 2026	January 1 to March 31, 2025 (after restatement)
Proceeds from disposal of financial assets at amortized cost	$ 48,875,207	$ 43,208,696
Purchase of financial assets at fair value through profit or loss	(137,347)	(383,618)
Proceeds from disposals of financial assets at fair value through profit or loss	-	234
Acquisition of investments accounted for using the equity method	(422,361)	(175,487)
Net cash inflow from acquisition of subsidiaries	-	740,071
Acquisition of property, plant and equipment	(229,609)	(152,772)
Proceeds from disposal of property, plant and equipment	82,003	158,209
Increase in refundable deposits	(160)	(4,347)
Decrease in refundable deposits	487	569
Acquisition of intangible assets	(8,743)	(2,831)
Interest received	1,095,266	1,238,175
Net cash used in investing activities	(22,051,539)	(11,805,944)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from short-term borrowings	134,799,888	144,416,461
Repayments of short-term borrowings	(130,598,608)	(143,578,704)
Proceeds from guarantee deposits received	-	658
Refunds of guarantee deposits received	-	(16,377)
Repayment of principal of lease liabilities	(5,456)	(2,086)
Distribution of cash dividends	(1,870,988)	(5,102,729)
Purchase of treasury shares	(7,942,648)	(4,782,379)
Acquisition of subsidiary shares	(19,078)	(56,421)
Interest paid	(321,121)	(249,393)
Proceeds from unclaimed dividends	837	1,208
Net cash used in financing activities	(5,957,174)	(9,369,762)
EFFECTS OF EXCHANGE RATE CHANGES ON THE BALANCE OF CASH AND CASH EQUIVALENTS HELD IN FOREIGN CURRENCIES	705,678	426,875
NET DECREASE IN CASH AND CASH EQUIVALENTS	(27,564,759)	(19,996,872)
OPENING CASH AND CASH EQUIVALENTS	43,747,619	50,364,287
CLOSING CASH AND CASH EQUIVALENTS	$ 16,182,860	$ 30,367,415

The accompanying notes are an integral part of the consolidated financial statements.

(Refer to the review report of Deloitte & Touche dated May 13, 2026)

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
JANUARY 1 TO MARCH 31, 2026 AND 2025

(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

1. GENERAL INFORMATION

Catcher Technology Co., Ltd. (the "Company") was incorporated in November 1984 under the laws of the Republic of China (R.O.C.). The Company mainly manufactures and sells aluminum and magnesium extrusion and stamping products and molds. It also provides leasing services.

The Company's shares were listed and traded on the Taipei Exchange (formerly called the GreTai Securities Market) from November 1999 until September 2001, when the Company listed its shares on the Taiwan Stock Exchange (TWSE) under stock number "2474" and ceased listing and trading on the Taipei Exchange.

The consolidated financial statements of the Company and its subsidiaries are presented in the Company's functional currency, the New Taiwan dollar.

2. APPROVAL OF FINANCIAL STATEMENTS

The consolidated financial statements were published after approval by the Company's Board of Directors on May 13, 2026.

3. APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS

a. Initial application of the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC interpretations (IFRIC) and SIC interpretations (SIC) (collectively, "IFRS Accounting Standards") endorsed and issued into effect by the Financial Supervisory Commission (FSC).

   The application of the IFRS Accounting Standards endorsed and issued into effect by the FSC did not have any material impact on the accounting policies of the Company and its subsidiaries (collectively referred to as the "Group").

b. IFRS Accounting Standards issued by the IASB but not yet endorsed and issued into effect by the FSC

New IFRSs	Effective Date Announced by IASB (Note 1)
Amendments to IFRS 10 and IAS 28 "Sale or Investment of Assets Between Investors and Their Affiliates or Joint Ventures"	To be announced
IFRS 18 "Presentation and Disclosure of Financial Statements"	January 1, 2027 (Note 2)
IFRS 19 "Subsidiaries without Public Accountability: Disclosures" (including 2025 amendments)	January 1, 2027
Amendments to IAS 21 "Translation to a Hyperinflationary Presentation Currency"	January 1, 2027

Note 1: Unless stated otherwise, the above new/revised/amended IFRSs are effective for the annual reporting periods beginning on or after their respective effective dates.

Note 2: On September 25, 2025, the Financial Supervisory Commission (FSC) announced that domestic companies shall apply IFRS 18 starting from January 1, 2028, and may elect early adoption after IFRS 18 has been endorsed by the FSC.

<u>IFRS 18 "Presentation and Disclosure of Financial Statements" and related supporting amendments</u>

IFRS 18 will replace IAS 1 “Presentation of Financial Statements”. Major changes include:

- The Group shall assess whether it has specific main business activities involving investments in particular types of assets and the provision of financing to customers. Based on such assessment, the income and expense items presented in the statement of profit or loss shall be classified into the categories of operating, investing, financing, income taxes, and discontinued operations.
- The income statement shall report operating profit and loss, profit and loss before financing and income tax, as well as subtotals and totals of profit and loss.
- Guidelines are provided to enhance the requirements for aggregation and segmentation: The Group shall identify assets, liabilities, equity, revenues, expenses, and cash flows arising from individual transactions or other matters, and classify and aggregate them based on shared characteristics. This ensures that each line item reported in the primary financial statements reflects at least one common characteristic. Items with dissimilar characteristics shall be segmented in the primary financial statements and notes. The Group shall label such items as “Other” only when more informative labels are not available.
- Increase the disclosure of performance measurements defined by management: When the Group engages in public communications outside of the financial statements and conveys management’s view on a particular aspect of the Group’s overall financial performance to users of the financial statements, it shall disclose, in a single note to the financial statements, information related to the performance measurement defined by management. This includes a description of the measurement, how it is calculated, a reconciliation to the subtotals or totals specified by IFRS, and the effects of the reconciliation items on income taxes and non-controlling interests.

In addition, the following supporting amendments were made to IAS 7 “Statement of Cash Flows”:

- When preparing cash flows from operating activities using the indirect method, the Group shall use operating profit or loss as the starting point for reconciliation.
- Interest and dividends received by the Group shall be classified as investing activities, while interest and dividends paid shall be classified as financing activities. If the Group determines that it has a specific main business activity, the classification of dividends received, interest received, and interest paid in the statement of cash flows shall be determined based on the nature of dividend income, interest income, and interest expense presented in the statement of profit or loss. However, each of the above cash flows may be classified into only one category of activities in the statement of cash flows.

In addition to the aforementioned impacts, as of the date these consolidated financial statements were authorized for issue, the Group is still assessing the effects of the amendments to the standards and interpretations on its financial position and financial performance. The related impacts will be disclosed upon completion of the assessment.

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

a. Statement of Compliance

The consolidated financial statements have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as endorsed and issued into effect by the FSC. The consolidated financial statements do not contain all of the disclosures required by IFRS Accounting Standards for the entire annual consolidated financial statements.

b. Basis of Preparation

The consolidated financial statements have been prepared on a historical cost basis, except for financial instruments measured at fair value and net defined benefit liabilities recognized at the present value of the defined benefit obligations less the fair value of plan assets.

The fair value measurements, which are grouped into Levels 1 to 3 based on the degree to which the relevant inputs are observable and significant, are described as follows:

1) Level 1 inputs: (unadjusted) prices quoted in active markets for identical assets or liabilities;

2) Level 2 inputs: other than quoted prices classified as Level 1 inputs, observable inputs for assets or liabilities, either directly obtained (i.e. prices) or indirectly derived (from prices);

3) Level 3 inputs: unobservable inputs for assets or liabilities.

c. Basis of Consolidation

The consolidated financial statements incorporate the financial statements of the Company and the entities controlled by the Company (i.e., its subsidiaries). The consolidated statement of comprehensive income includes the operating results of the acquired subsidiaries from the acquisition date during the period. Adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with those of the Group. All intra-group transactions, balances, income, expenses and losses are eliminated in full upon consolidation. Total comprehensive income of subsidiaries is attributed to the owners of the Company and the non-controlling interests even if this leads to a deficit balance for the non-controlling interests.

Changes in the Group's ownership interests in subsidiaries that do not result in the Group losing control over its subsidiaries are accounted for as equity transactions. The carrying amounts of the interests of the Group and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the Company.

For details of subsidiaries, the parent's shareholding ratios, and main businesses of subsidiaries, please refer to Note 13, Tables 6 and 7.

d. Other material accounting policies

In addition to the following descriptions, please refer to the summary of material accounting policies in the 2025 Consolidated Financial Statements.

1) Derecognition of financial liabilities

Financial liabilities are derecognized on the settlement date, which is the date when the obligation specified in the contract is discharged, cancelled, or expires, or when an exchange of debt instruments with substantially different terms occurs, or when the terms of an existing liability are substantially modified. Upon derecognition of a financial liability, the difference between the carrying amount of the liability and the consideration paid (including any non-cash assets transferred or liabilities assumed) is recognized in profit or loss.

2) Defined benefit retirement benefits

The pension cost in the interim period is calculated based on the actuarially determined pension cost rate at the end of the previous year, from the beginning of the year to the end of the current period. Adjustments are also made for major market fluctuations in the current period, as well as major plan revisions, liquidations, or other major one-off events.

3) Taxation

Income tax expense represents the sum of the tax currently payable and tax deferred. Income tax for the interim period is assessed on an annual basis and is calculated based on the interim pre-tax profit using the tax rate applicable to the expected total annual profit.

5. MATERIAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

Please refer to the description of the major sources of uncertainty in material accounting judgments, estimates and assumptions in the 2025 consolidated financial statements.

6. CASH AND CASH EQUIVALENTS

	March 31, 2026	December 31, 2025	March 31, 2025
Cash on hand	$ 1,635	$ 1,973	$ 3,016
Demand deposits in banks	6,741,489	13,484,697	6,950,875
Cash equivalents (investments with initial maturities of less than 3 months)			
Time deposits	9,176,736	30,002,949	23,403,024
Repurchase agreements	263,000	258,000	10,500
	$16,182,860	$43,747,619	$30,367,415

The interest rate ranges of time deposits and repurchase agreements were as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Time deposits	0.77%~4.03%	0.52%~6.15%	0.40%~6.15%

Repurchase agreements	1.29%~1.32%	1.29%	1.28%

7. FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS (FVTPL)

	March 31, 2026	December 31, 2025	March 31, 2025
Financial assets - current			
Mandatorily measured at FVTPL			
Non-derivative financial assets			
- Mutual funds	$ 674,543	$ 644,757	$ 505,631
- Listed stocks	554	604	597
	$ 675,097	$ 645,361	$ 506,228
Financial assets - non-current			
Mandatorily measured at FVTPL			
Non-derivative financial assets			
- Private equity funds	$ 2,914,085	$ 2,817,509	$ 2,707,901
- Limited partnerships	250,246	249,877	252,819
- Simple Agreement for Future Equity (SAFE)	26,072	26,072	-
- Foreign non-listed stocks	34,038	33,437	35,325
	$ 3,224,441	$ 3,126,895	$ 2,996,045

8. FINANCIAL ASSETS MEASURED AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME (FVTOCI)

	March 31, 2026	December 31, 2025	March 31, 2025
Current			
Investments in equity instruments	$ 9,035,133	$ 8,453,326	$ 6,091,857
Non-Current			
Investments in equity instruments	$ 2,599,785	$ 2,241,428	$ 2,697,877
Investments in debt instruments	80,942,330	81,716,922	88,272,201
	$83,542,115	$83,958,350	$90,970,078

a. Investments in equity instruments

	March 31, 2026	December 31, 2025	March 31, 2025
Current			
Domestic investments			
Listed stocks	$ 6,876,279	$ 6,749,002	$ 5,365,997
Foreign investments			
Listed stocks	2,158,854	1,704,324	725,860
	$ 9,035,133	$ 8,453,326	$ 6,091,857
Non-Current			
Domestic investments			
Non-listed stocks	$ 303,521	$ 302,340	$ 248,604
Foreign investments			
Limited partnerships	1,765,145	1,548,752	2,188,208
Listed stocks	531,119	390,336	261,065
	$ 2,599,785	$ 2,241,428	$ 2,697,877

The investments in equity instruments are held for medium- to long-term strategic purpose and are expected to generate long-term profits. Accordingly, the management decided to designate and evaluate the investments in equity instruments at FVTOCI as they believe that recognizing profit or loss from short-term fair value fluctuations of these investments is not consistent with the Group's long-term investment plan.

The Group increased its investment in China Renewable Energy Fund, L.P. (the CREF) to 23.51%. Holding only 1 out of 5 seats in the Operation Committee of the CREF and considering this as having no significant influence over the investee, the management of the Group decided to classify the investment as financial assets at FVTOCI - non-current.

The Group holds 20% of the equity interests in Intai Technology Corp. and Drewloong Precision, Inc. The Group's management determined that the Group does not exercise significant influence over these investees. Therefore, these investments were classified as financial assets at fair value through other comprehensive income (FVOCI) – current.

In January 2025, the Group's shareholding in United Orthopedic Corporation reached 20%. The Group assessed that it has significant influence over the investee. Accordingly, starting from January 15, 2025, the accounting treatment for the investment has been changed from financial assets measured at fair value through other comprehensive income to investments accounted for using the equity method, based on the closing price on that date. Please refer to Note 14.
The Group holds 20% of the equity of TwHealth Nexus Inc. The Group's management determined that the Group does not exercise significant influence over the investee. Therefore, these investments were classified as financial assets at fair value through other comprehensive income (FVOCI) – non-current.

b. Investments in debt instruments

	March 31, 2026	December 31, 2025	March 31, 2025
Non-Current			
Corporate bonds	$ 721,291	$ 2,022,665	$ 3,072,303
Government bonds	80,221,039	79,694,257	85,199,898
	$80,942,330	$81,716,922	$88,272,201

Refer to Note 10 for information relating to the credit risk management and impairment of investments in debt instruments at FVTOCI.

9. FINANCIAL ASSETS MEASURED AT AMORTIZED COST

	March 31, 2026	December 31, 2025	March 31, 2025
Current			
Domestic investments			
Time deposits with original maturity of more than 3 months (1)	$53,908,368	$34,690,583	$37,591,343
Restricted bank deposits (1 and 3)	4,015,487	-	3,020,155
Time deposits in offshore fund accounts (1)	17,757,479	17,481,065	27,083,156
Refundable deposits	5,590	5,448	5,648
	$75,686,924	$52,177,096	$67,700,302

(Continued)

(Continued from previous page)

	March 31, 2026	December 31, 2025	March 31, 2025
Non-Current			
Domestic investments			
Corporate bonds (2)	$ 9,835	$ 9,820	$ -
Refundable deposits	17,933	18,282	909
	$ 27,768	$ 28,102	$ 909

a. The interest rate range of time deposits as of the balance sheet date was as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Time deposits	0.76%~4.20%	1.60%~4.53%	1.44%~5.32%

b. In November 2025, the consolidated company purchased NT$10,000 thousand par value of Taiwan Semiconductor Manufacturing Company Limited (TSMC) 2022 First Series Unsecured Ordinary Corporate Bonds. The bond carries a coupon rate of 0.72%, with an effective interest rate of 1.32767%. The investment counterparties are financial institutions and corporations with strong credit quality. Accordingly, the probability of default is considered to be very low.

c. For information on pledges of assets measured at amortized cost - current, please refer to Note 34.

10. CREDIT RISK MANAGEMENT FOR INVESTMENTS IN DEBT INSTRUMENTS

Debt instruments invested by the Group are financial assets measured at fair value through other comprehensive income (FVTOCI):

March 31, 2026

	Financial Assets at FVTOCI
Gross carrying amount	$ 80,977,467
Allowance for impairment loss	(35,137)
	$ 80,942,330

December 31, 2025

	Financial Assets at FVTOCI
Gross carrying amount	$ 81,751,438
Allowance for impairment loss	(34,516)
	$ 81,716,922

March 31, 2025

	Financial Assets at FVTOCI
Gross carrying amount	$ 88,308,667
Allowance for impairment loss	(36,466)
	$ 88,272,201

The Group invests in debt instruments with credit rating information supplied by independent rating agencies. The Group continues to track external rating information to monitor changes in the credit risk of the invested debt instruments, while reviewing other information such as bond yield curves and major information of the debtors to assess whether the credit risk of the debt instrument investments has increased significantly since initial recognition.

The Group takes into consideration a variety of historical default risks and loss ratios provided by external rating agencies, the debtors' current financial status and the outlook of the industry where it belongs to, to measure the expected credit loss of 12 months or the expected credit loss for the duration of the investment in debt instruments.

The Group currently adopts the following credit risk rating mechanism:

Credit Rating	Definition	Recognition Basis for Expected Credit Loss
Normal	The debtor has low credit risk and sufficient ability to repay the contractual cashflows	Expected credit losses for 12-month
Abnormal	Credit risk has increased significantly since initial recognition	Expected credit loss for the duration of the debt instrument investment (without credit impairment)
Default	Evidence of credit impairment	Expected credit loss for the duration of the debt instrument investment (with credit impairment)
Offset	There is evidence that the debtor is facing severe financial difficulties and that the Group has no reasonable expectation of recovery	Direct write-off

The carrying amount of investments in debt instruments for each credit rating and the applicable expected credit loss ratio are as follows:

March 31, 2026

		Gross Carrying Amount
Credit Rating	Expected Credit Loss Ratio	Financial Assets at FVTOCI
Normal	0%	$ 80,942,330
Abnormal	100%	35,137

December 31, 2025

		Gross Carrying Amount
Credit Rating	Expected Credit Loss Ratio	Financial Assets at FVTOCI
Normal	0%	$ 81,716,922
Abnormal	100%	34,516

March 31, 2025

		Gross Carrying Amount
Credit Rating	Expected Credit Loss Ratio	Financial Assets at FVTOCI
Normal	0%	$ 88,272,201
Abnormal	100%	36,466

Information on changes in loss allowances on debt instrument investments measured at fair value through other comprehensive income:

	Abnormal credit rating (Expected credit loss without credit impairment, over the duration)
Balance at January 1, 2026	$ 34,516
Exchange rate movement	621
Balance at March 31, 2026	$ 35,137
Balance at January 1, 2025	$ 36,004
Exchange rate movement	462
Balance at March 31, 2025	$ 36,466

11. TRADE RECEIVABLES AND OTHER RECEIVABLES

	March 31, 2026	December 31, 2025	March 31, 2025
Notes receivable			
At amortized cost – not incurred from operations			
Gross carrying amount	$ 9,632	$ 12,275	$ 14,748
Trade receivables			
At amortized cost			
Gross carrying amount	$ 3,488,642	$ 4,072,787	$ 5,574,345
Less: allowance for impairment loss	(19,068)	(8,309)	(8,311)
	$ 3,469,574	$ 4,064,478	$ 5,566,034
Other receivables			
Interest receivable	$ 1,664,200	$ 1,071,146	$ 1,972,326
Others	99,736	80,957	62,458
	$ 1,763,936	$ 1,152,103	$ 2,034,784

a. Notes receivable

Loss allowance is not provided as historical experiences suggest that the possibility of recovery for notes receivables is extremely high.

b. Trade receivables

The average credit period for sales of goods is 30 to 180 days, and there is no interest charged on trade receivables. In order to minimize credit risk, the Group's management has delegated a team responsible for determining credit limits, credit approvals and other monitoring procedures to ensure that appropriate actions are taken to recover receivables past due. In addition, the Group reviews the recoverable amount of each individual receivable at the end of the reporting period to ensure that adequate loss allowance is provided against irrecoverable receivables. Thus, the management believes that the Group's credit risk has been significantly reduced.

The Group recognizes the loss allowance for trade receivables based on the lifetime expected credit losses (ECLs). The lifetime ECLs are calculated using a provision matrix by referring to clients' past default records, current financial status and industry conditions, while also taking into account the economic and industry outlook. The provision matrix determines the expected credit loss ratio based on the number of days that a trade receivable is past due, with no further client segmentation, considering there is no significant difference between the loss patterns of different customer groups.

The Group writes off a trade receivable when seeing evidences that the debtor is in severe financial difficulties and there is no realistic prospect of recovery. For instance, when the trade counterpart is under liquidation. For trade receivables that have been written off, the Group continues to engage in enforcement activities in an attempt to recover the receivables past due. The recovered amount will be recognized as profit or loss.

The following table details the loss allowance of trade receivables based on the Group's provision matrix:

March 31, 2026

	Not past due	1-60 days past due	61-120 days past due	121-180 days past due	More than 180 days past due	Total
Expected credit loss ratio	0%~0.019%	0%~19.411%	0%~24.704%	0%~23.222%	10%~100%	
Gross carrying amount	$ 3,195,513	$ 290,240	$ 1,597	$ 594	$ 698	$ 3,488,642
Loss allowance (lifetime ECLs)	(621)	(17,669)	(80)	-	(698)	(19,068)
Amortized cost	$ 3,194,892	$ 272,571	$ 1,517	$ 594	$ -	$ 3,469,574

December 31, 2025

	Not past due	1-60 days past due	61-120 days past due	121-180 days past due	More than 180 days past due	Total
Expected credit loss ratio	0%~0.05%	0%~20.071%	0%~26.514%	0%~17.165%	10%~100%	
Gross carrying amount	$ 3,965,237	$ 97,952	$ 8,900	$ -	$ 698	$ 4,072,787
Loss allowance (lifetime ECLs)	(1,986)	(3,781)	(1,844)	-	(698)	(8,309)
Amortized cost	$ 3,963,251	$ 94,171	$ 7,056	$ -	$ -	$ 4,064,478

March 31, 2025

	Not past due	1-60 days past due	61-120 days past due	121-180 days past due	More than 180 days past due	Total
Expected credit loss ratio	0%~0.152%	0%~2.031%	0%~4.762%	0%~4.348%	10%~100%	
Gross carrying amount	$ 5,429,101	$ 137,678	$ 7,534	$ 11	$ 21	$ 5,574,345
Loss allowance (lifetime ECLs)	(8,245)	(49)	(15)	-	(2)	(8,311)
Amortized cost	$ 5,420,856	$ 137,629	$ 7,519	$ 11	$ 19	$ 5,566,034

Information on changes in the loss allowance of trade receivables is as follows:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Opening balance	$ 8,309	$ 8,309
Plus: allowance for doubtful accounts recognized this period	10,759	2
Ending balance	$ 19,068	$ 8,311

c. Other receivables

Loss allowance is not provided as historical experiences suggest that the possibility of recovery for notes receivables is extremely high.

12. INVENTORIES

	March 31, 2026	December 31, 2025	March 31, 2025
Merchandise	$ 6,841	$ 7,794	$ 97,561
Finished goods	2,760,500	2,086,025	1,420,532
Work-in-process and semi-finished goods	729,100	921,774	663,099
Raw materials and supplies	389,672	421,103	315,305
	$ 3,886,113	$ 3,436,696	$ 2,496,497

The nature of the cost of goods sold is as follows:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Cost of inventories sold	$ 2,763,186	$ 2,981,468
Inventory write-down	3,580	4,359
Others	(79,805)	(159,148)
	$ 2,686,961	$ 2,826,679

13. SUBSIDIARY

a. Subsidiaries included in the consolidated financial statements

The reporting entities of the consolidated financial statements were as follows:

			Shareholding percentage (%)			
Investor Company	Investee	Main Business	March 31, 2026	December 31, 2025	March 31, 2025	Remark
Catcher Technology Co., Ltd.	Nanomag International Co., Ltd.	Investing activities	100	100	100	
	Gigamag Co., Ltd.	Investing activities	100	100	100	
	Ke Yue Co., Ltd.	Investing activities	100	100	100	
	Yi Sheng Co., Ltd.	Investing activities	100	100	100	
	Yi De Co., Ltd.	Investing activities	100	100	100	
	Catcher Medtech Co., Ltd.	Manufacturing and selling medical devices	100	100	100	
	Catcher Holdings International Inc.	Investing activities	100	100	-	Note 1
	Yi Fa Co., Ltd.	Investing activities	100	100	100	
	Yi Chuan Co., Ltd.	Investing activities	100	100	100	
	Yi Zhu Co., Ltd.	Investing activities	100	100	100	
	Xincher Precision Manufacturing Co., Ltd.	Manufacturing and selling varied alloy products	100	100	100	
	Topo Technology (Thailand) Co., Ltd.	Manufacturing and selling varied alloy products	100	100	100	
Ke Yue Co., Ltd.	Pacific Hospital Supply Co., Ltd.	Manufacturing and selling medical devices	10.42	10.42	10.42	Note 3
Yi Sheng Co., Ltd.	Pacific Hospital Supply Co., Ltd.	Manufacturing and selling medical devices	4.48	4.48	4.48	Note 3

(Continued)

(Continued from previous page)

Investor Company	Investee	Main Business	Shareholding percentage (%) March 31, 2026	December 31, 2025	March 31, 2025	Remark
Yi De Co., Ltd.	Pacific Hospital Supply Co., Ltd.	Manufacturing and selling medical devices	5.57	5.57	5.57	Note 3
Catcher Medtech Co., Ltd.	Ren He Medtech Co., Ltd.	Selling medical devices	100	100	100	
	Ren Yi Medtech Co., Ltd.	Selling medical devices	100	100	100	
	COFORCE Medical Inc.	CDMO business for medical devices	100	100	100	
	Pacific Hospital Supply Co., Ltd.	Manufacturing and selling medical devices	4.14	4.14	4.14	Note 3
Yi Fa Co., Ltd.	Pacific Hospital Supply Co., Ltd.	Manufacturing and selling medical devices	8.45	8.45	7.81	Note 3
Yi Chuan Co., Ltd.	Pacific Hospital Supply Co., Ltd.	Manufacturing and selling medical devices	1.85	1.51	-	Note 3
Nanomag International Co., Ltd.	Castmate International Co., Ltd.	Investing activities	-	-	-	Note 2
	Stella International Co., Ltd.	Investing activities	100	100	100	
	Uranus International Co., Ltd.	Investing activities	100	100	100	
	Norma International Co., Ltd.	Investing activities	100	100	100	
	Next Level Ltd.	Investing activities	100	100	100	
	Cor Ventures Pte. Ltd.	Investing activities	100	100	100	
Stella International Co., Ltd.	Lyra International Co., Ltd.	Investing activities	100	100	100	
Uranus International Co., Ltd.	Catcher Technology (Suqian) Co., Ltd.	Manufacturing, selling and developing varied alloy products	100	100	100	
	Vito Technology (Suqian) Co., Ltd.	Manufacturing, selling and developing varied alloy products	100	100	100	
Norma International Co., Ltd.	Arcadia Technology (Suqian) Co., Ltd.	Manufacturing, selling and developing varied alloy products	100	100	100	
	Envio Technology (Suqian) Co., Ltd.	Manufacturing, selling and developing varied alloy products	100	100	100	
Catcher Holdings International Inc.	Catcher Ventures Inc.	Investing activities	100	100	-	Note 1

Note 1: The Company established Catcher Holdings International Inc. and Catcher Ventures Inc. in June 2022, and remitted the related investment funds in August 2025.

Note 2: The Board of Directors resolved in February 2024 to liquidate Aquila International Co., Ltd., which was liquidated and deregistered in January 2025.

Note 3: In January 2025, the Group obtained de facto control over Pacific Hospital Supply Co., Ltd. Accordingly, starting from January 2025, the company has been included as a subsidiary in the consolidated financial statements. The original investment in Pacific Hospital Supply Co., Ltd. accounted for using the equity method was deemed disposed of, and a gain on disposal of investments accounted for using the equity method in the amount of NT$480,772 thousand was recognized under other gains and losses. The Group completed the purchase price allocation report during the fourth quarter of 2025 and has adjusted the initial accounting treatment and provisional amounts since the date of acquisition, with restatement of comparative information. Please refer to Note 29 for information on the restatement.

b. Significant information on subsidiaries of non-controlling interests

Investee	Percentage of ownership and voting rights held by non-controlling interests March 31, 2026	December 31, 2025	March 31, 2025
Pacific Hospital Supply Co., Ltd.	65.09%	65.44%	67.58%

For information on the principal place of business and the country of incorporation, please refer to Table 6.

Investee	Profit or loss allocated to non-controlling interests January 1 to March 31, 2026	January 1 to March 31, 2025
Pacific Hospital Supply Co., Ltd.	$ 51,050	$ 72,227

Investee	Non-controlling interests March 31, 2026	December 31, 2025	March 31, 2025
Pacific Hospital Supply Co., Ltd.	$ 3,390,905	$ 3,350,355	$ 3,539,081

The summarized financial information of the following subsidiaries is presented before intercompany eliminations:

Pacific Hospital Supply Co., Ltd.

	March 31, 2026	December 31, 2025	March 31, 2025
Current assets	$ 1,902,979	$ 1,822,506	$ 1,896,668
Non-current assets	2,074,453	2,096,761	2,102,162
Current liabilities	(476,788)	(522,288)	(498,407)
Non-current liabilities	(428,737)	(429,540)	(425,468)
Equity	$ 3,071,907	$ 2,967,439	$ 3,074,955

(Continued)

(Continued from previous page)

	March 31, 2026	December 31, 2025	March 31, 2025
Equity attributable to:			
Owners of the Company	$ 1,072,417	$ 1,025,688	$ 996,861
Non-controlling interests of Pacific Hospital Supply Co., Ltd.	1,999,490	1,941,751	2,078,094
	$ 3,071,907	$ 2,967,439	$ 3,074,955

	January 1 to March 31, 2026	January 1 to March 31, 2025
Operating revenue	$ 581,571	$ 604,537
Total net income and comprehensive income	$ 104,468	$ 132,719
Total net income and comprehensive income attributable to:		
Owners of the Company	$ 36,229	$ 42,630
Non-controlling interests of Pacific Hospital Supply Co., Ltd.	68,239	90,089
	$ 104,468	$ 132,719
Cash flow		
Operating activities	$ 67,175	$ 57,957
Investing activities	(182,976)	(60,333)
Financing activities	(4,546)	(4,030)
Effects of exchange rate changes on the balance of cash and cash equivalents	1,857	16,838
Net cash inflow (outflow)	($ 118,490)	$ 10,432

14. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

	March 31, 2026	December 31, 2025	March 31, 2025
Investments in associates			
Associates that are not individually material			
Bioteque Corporation	$ 2,310,410	$ 2,256,976	$ 2,002,501
United Orthopedic Corporation	2,450,310	2,346,393	1,955,306
Smart Ecare Inc.	3,673	3,657	3,667
Niche Biomedical Inc.	319,950	-	-
	$ 5,084,343	$ 4,607,026	$ 3,961,474

Information of associates that are not individually material was as follows:

	January 1 to March 31, 2026	January 1 to March 31, 2025
The Group's share of:		
Current-period net profit	$ 42,389	$ 49,671
Other comprehensive income	6,647	9,935
Total comprehensive income	$ 49,036	$ 59,606

As stated in Note 8, the Group held ordinary shares of United Orthopedic Corporation, which were reclassified from financial assets measured at fair value through other comprehensive income to investments using the equity method on January 15, 2025. The Group completed the purchase price allocation report in the first quarter of 2026. Therefore, the previously issued consolidated financial statements were retrospectively restated in accordance with the applicable regulations. Please refer to Note 29 for information on the restatement.

The investment in Smart Ecare Inc., Niche Biomedical Inc. accounted for using the equity method, and the profit and loss as well as other comprehensive income shared with the Group, are calculated based on the financial statements which were not reviewed by CPAs. The management of the Group nevertheless believes this would not have a material impact.

15. PROPERTY, PLANT AND EQUIPMENT

All property, plant and equipment are used by the Group.

Please refer to Table 9 for the changes in property, plant, and equipment of the Group from January 1 to March 31 in 2026 and 2025.

The Group’s property, plant, and equipment are depreciated on a straight-line basis over their estimated useful lives as follows:

Buildings	
Main buildings	20-51 years
Mechanical and electrical power equipment	5-30 years
Engineering systems	2-5 years
Others	2-50 years
Machinery and equipment	2-26 years
Miscellaneous equipment	2-15 years

All of the Group’s property, plant and equipment are not pledged as collateral.

16. LEASE ARRANGEMENTS

a. Right-of-use assets

	March 31, 2026	December 31, 2025	March 31, 2025
Carrying amount			
Land	$ 1,342,602	$ 1,325,207	$ 1,380,034
Buildings	22,561	25,625	20,638
Transportation equipment	2,479	2,656	-
	$ 1,367,642	$ 1,353,488	$ 1,400,672

	January 1 to March 31, 2026	January 1 to March 31, 2025
Addition to right-of-use assets	$ 1,044	$ 11,769
Depreciation charge		
Land	$ 9,106	$ 9,147
Buildings	4,261	3,236
Transportation equipment	177	-
	$ 13,544	$ 12,383

Except for the above additions and recognition of depreciation expenses, there were no significant sublease or impairment events for the right-of-use assets of the Group and its subsidiaries during the period from January 1 to March 31, 2026 and 2025, respectively.

b. Lease liabilities

	March 31, 2026	December 31, 2025	March 31, 2025
Carrying amount of lease liabilities			
Current	$ 22,736	$ 24,798	$ 30,912
Non-Current	$ 532,916	$ 535,092	$ 533,856

The range of discount rates for lease liabilities was as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Land	1.32%~1.82%	1.32%~1.82%	1.32%~1.82%
Buildings	1.79%~5%	1.79%~5%	1.79%~5%
Transportation equipment	2.2%	2.2%	-

c. Material leasing activities and terms

The Group leases certain land and buildings for the use of plants and office spaces with lease terms of 3 to 50 years. The lease contract for land located in Taiwan specifies that lease payments will be adjusted every year on the basis of changes in the announced land value prices. The lease contract for land located in China specifies that lease payments will be adjusted every year based on the lease contract. The Group does not have bargain purchase options to acquire the leasehold land and buildings at the end of the lease terms. In addition, the Group is prohibited from subleasing or transferring all or any portion of the underlying assets without consent of the lessors. Furthermore, the subsidiary, Pacific Hospital Supply Co., Ltd., has a renewal option for the leased land.

d. Other lease information

	January 1 to March 31, 2026	January 1 to March 31, 2025
Expenses relating to short-term leases	$ 1,931	$ 886
Expenses relating to low-value asset leases	$ 140	$ 199
Expenses relating to variable lease payments not included in the measurement of lease liabilities	$ 1,106	$ 921
Total cash outflow for leases	$ 11,230	$ 2,427

The Group has elected to apply the recognition exemption to certain asset leases which qualify as short-term leases and low-value asset leases. Thus, right-of-use assets and lease liabilities are not recognized for these leases.

17. INVESTMENT PROPERTIES

	Land	Buildings	Total
Costs			
Balance at January 1, 2025	$ 1,108,694	$ 211,518	$ 1,320,212
Acquisition through business combination (Note 29)	119,545	60,520	180,065
Balance at March 31, 2025	$ 1,228,239	$ 272,038	$ 1,500,277
Accumulated depreciation			
Balance at January 1, 2025	$ -	$ 155,288	$ 155,288
Depreciation expense	-	872	872
Balance at March 31, 2025	$ -	$ 156,160	$ 156,160
Net amount as of March 31, 2025	$ 1,228,239	$ 115,878	$ 1,344,117
Costs			
Balance at January 1 and March 31, 2026	$ 1,108,694	$ 212,478	$ 1,321,172
Accumulated depreciation			
Balance at January 1, 2026	$ -	$ 156,843	$ 156,843
Depreciation expense	-	434	434
Balance at March 31, 2026	$ -	$ 157,277	$ 157,277
Net amount as of December 31, 2025 and January 1, 2026	$ 1,108,694	$ 55,635	$ 1,164,329
Net amount as of March 31, 2026	$ 1,108,694	$ 55,201	$ 1,163,895

Depreciation of investment properties are calculated using the straight-line method over their estimated useful lives as follows:

Main buildings	25-50 years
Elevators	15 years
Heat dissipation system	5 years

The fair values of the Group's investment properties as of December 31, 2025 and 2024 were NT$2,856,399 thousand and NT$2,152,911 thousand, respectively. As assessed by the management of the Group, there was no significant change in the fair value as of March 31, 2026 and 2025 compared to December 31, 2025 and 2024.

In addition, in January 2025, the Group acquired land and buildings through a business combination in the amount of NT$90,949 thousand. The fair value of the assets was NT$124,542 thousand, as appraised by Euro-Asia Real Estate Appraisers Firm on December 31, 2024. The valuation was based on market evidence of transaction prices of comparable properties.

All of the Group's investment properties were not pledged as collateral.

The investment properties are leased for a period from February 2017 to July 2029. The lessees agree to extend lease contracts with the rental adjusted based on market conditions. The lessees do not have bargain purchase options to acquire the investment properties at the expiry of the leasing period.

The lease payment receivables from investment properties under an operating lease were as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Year 1	$ 24,781	$ 26,260	$ 32,595
Year 2	6,475	10,919	24,781
Year 3	5,257	5,257	6,475
Year 4	1,752	3,067	5,257
Year 5	-	-	1,752
	$ 38,265	$ 45,503	$ 70,860

18. GOODWILL AND INTANGIBLE ASSETS

	Goodwill	Computer Software	Technical Skills	Patent Right	Customer Relations	Trademark Right	Other Intangible Assets	Total
Costs								
Balance at January 1, 2025	$ 115,089	$ 387,812	$ 29,700	$ 940	$ -	$ -	$ 65,951	$ 599,492
Separate acquisition	-	6,185	-	-	-	-	-	6,185
Acquisition through business combination (Note 29)	623,277	6,442	-	353,000	474,000	198,000	-	1,654,719
Disposal	-	(34)	-	-	-	-	-	(34)
Effect of foreign currency exchange difference	-	2,207	-	-	-	-	-	2,207
Balance at March 31, 2025	$ 738,366	$ 402,612	$ 29,700	$ 353,940	$ 474,000	$ 198,000	$ 65,951	$ 2,262,569
Accumulated amortization								
Balance at January 1, 2025	$ -	$ 374,716	$ 29,700	$ -	$ -	$ -	$ -	$ 404,416
Amortization expense	-	4,792	-	8,836	10,357	-	5,476	29,461
Disposal	-	(34)	-	-	-	-	-	(34)
Effect of foreign currency exchange difference	-	2,160	-	-	-	-	-	2,160
Balance at March 31, 2025	$ -	$ 381,634	$ 29,700	$ 8,836	$ 10,357	$ -	$ 5,476	$ 436,003
Net amount at March 31, 2025	$ 738,366	$ 20,978	$ -	$ 345,104	$ 463,643	$ 198,000	$ 60,475	$ 1,826,566
Costs								
Balance at January 1, 2026	$ 738,366	$ 404,778	$ 29,700	$ 354,428	$ 474,000	$ 198,000	$ 65,951	$ 2,265,223
Separate acquisition	-	10,454	-	-	-	-	-	10,454
Disposal	-	(281)	-	-	-	-	-	(281)
Effect of foreign currency exchange difference	-	5,092	-	-	-	-	-	5,092
Balance at March 31, 2026	$ 738,366	$ 420,043	$ 29,700	$ 354,428	$ 474,000	$ 198,000	$ 65,951	$ 2,280,488
Accumulated amortization								
Balance at January 1, 2026	$ -	$ 383,497	$ 29,700	$ 35,363	$ 41,429	$ -	$ 21,903	$ 511,892
Amortization expense	-	5,741	-	8,844	10,357	-	3,738	28,680
Disposal	-	(281)	-	-	-	-	-	(281)
Effect of foreign currency exchange difference	-	4,996	-	-	-	-	-	4,996
Balance at March 31, 2026	$ -	$ 393,953	$ 29,700	$ 44,207	$ 51,786	$ -	$ 25,641	$ 545,287
Net amount as of December 31, 2025 and January 1, 2026	$ 738,366	$ 21,281	$ -	$ 319,065	$ 432,571	$ 198,000	$ 44,048	$ 1,753,331
Net amount at March 31, 2026	$ 738,366	$ 26,090	$ -	$ 310,221	$ 422,214	$ 198,000	$ 40,310	$ 1,735,201

The above intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:

Computer software	1-10 years
Technical skills	5 years
Patent right	3-18 years
Customer relations	14 years
Other intangible assets	1-14 years

In the fourth quarter of 2024, the Group entered into an agreement with an unrelated party to purchase operating assets. The Group obtained the purchase price allocation report during the fourth quarter of 2025 and has adjusted the initial accounting treatment and provisional amounts since the date of acquisition, with restatement of comparative information. Please refer to Note 29 for information on the restatement.

19. OTHER ASSETS

	March 31, 2026	December 31, 2025	March 31, 2025
Current			
Office supplies	$ 215,414	$ 112,686	$ 89,782
Prepaid expenses	242,675	195,916	133,104
Net input VAT	36,561	115,761	118,213
Others	7,505	12,134	13,263
	$ 502,155	$ 436,497	$ 354,362
Non-Current			
Prepaid equipment	$ 266,419	$ 243,056	$ 102,342
Prepaid land payments	912,162	934,262	932,490
Others	261	391	495
	$ 1,178,842	$ 1,177,709	$ 1,035,327

20. SHORT-TERM BORROWINGS

	March 31, 2026	December 31, 2025	March 31, 2025
Unsecured bank loans	$58,514,098	$62,078,414	$45,662,203
Secured bank loans (Note 34)	7,900,000	-	2,450,260
	$66,414,098	$62,078,414	$48,112,463

The interest rate ranges for short-term borrowings were as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Unsecured bank loans	1.81%~2.25%	1.81%~2.40%	1.82%~2.65%
Secured bank loans	1.78%~1.81%	-	1.81%~2.55%

21. NOTES PAYABLE AND ACCOUNTS PAYABLE

The Group’s notes payable and accounts payable resulted from operating activities.

The Group has stipulated financial risk management policies in place to ensure that all payables are paid in accordance with the pre-agreed credit terms.

22. OTHER LIABILITIES

	March 31, 2026	December 31, 2025	March 31, 2025
Current			
Other payables			
Payables for technical service fees	$ 1,102,742	$ 1,068,208	$ 1,153,817
Payables for compensation of employees	835,191	958,404	1,239,335
Payables for salaries and bonuses	522,501	941,838	566,929

(Continued)

(Continued from previous page)

	March 31, 2026	December 31, 2025	March 31, 2025
Payables for office supplies	159,309	149,614	121,427
Payables for unused annual leave	135,107	135,594	141,528
Payables for purchases of equipment	103,143	101,515	60,265
Payables for taxes	60,385	71,040	82,048
Payables for utilities	50,888	75,702	59,088
Payables for maintenance	40,344	34,346	44,793
Payables for meals	28,128	33,860	20,316
Payables for shipping and warehousing expenses	27,990	45,922	29,117
Payables for interest	27,057	44,911	32,733
Payables for professional service fees	9,817	11,995	22,427
Payable for purchase of treasury shares	399,030	311,763	-
Others	320,467	404,348	366,582
	$ 3,822,099	$ 4,389,060	$ 3,940,405
Other liabilities			
Other advances received	$ 304,471	$ 674,468	$ 964,463
Guarantee deposits received	13,646	13,197	12,903
Payables for value-added tax	-	52,786	85,333
Others	21,873	18,341	18,721
	$ 339,990	$ 758,792	$ 1,081,420
Non-Current			
Other liabilities			
Guarantee deposits received	$ 13,909	$ 13,909	$ 15,656
Others	8,264	8,264	-
	$ 22,173	$ 22,173	$ 15,656

23. RETIREMENT BENEFIT PLANS

The pension expenses related to the defined benefit plan recognized from January 1 to March 31 in 2026 and 2025 were NT$1,036 thousand and NT$875 thousand, respectively, calculated based on the pension cost ratio actuarially determined on December 31, 2025, and 2024.

24. EQUITY

a. Common share capital

	March 31, 2026	December 31, 2025	March 31, 2025
Number of shares authorized (in thousands)	1,000,000	1,000,000	1,000,000
Authorized capital	$10,000,000	$10,000,000	$10,000,000
Number of shares issued and fully paid (in thousands)	561,369	592,169	680,364
Shares issued	$ 5,613,691	$ 5,921,691	$ 6,803,641

Fully paid ordinary shares, with a par value of NT$10, carry one vote per share and carry a right to dividends.

On April 16, 2025, the Company's Board of Directors approved a capital reduction to cancel the Company's 31,219 thousand treasury shares, and fixed the record date at April 18, 2025. The Company's paid-in capital was NT$6,491,451 thousand after the capital reduction.

On August 8, 2025, the Company's Board of Directors approved a capital reduction to cancel the Company's 25,476 thousand treasury shares, and fixed the record date at August 13, 2025. The Company's paid-in capital was NT$6,236,691 thousand after the capital reduction.

On December 23, 2025, the Company's Board of Directors approved a capital reduction to cancel the Company's 31,500 thousand treasury shares, and fixed the record date at December 26, 2025. The Company's paid-in capital was NT$5,921,691 thousand after the capital reduction.

On March 3, 2026, the Company's Board of Directors approved a capital reduction to cancel the Company's 30,800 thousand treasury shares, and fixed the record date at March 5, 2026. The Company's paid-in capital was NT$5,613,691 thousand after the capital reduction.

A total of 23,000 thousand shares of the Company's authorized shares were reserved for the issuance of employee stock options.

b. Capital surplus

	March 31, 2026	**December 31, 2025**	**March 31, 2025**
May be used to offset deficits, distributed as cash dividends, or transferred to share capital (1)			
Issuance premium	$ 5,436,164	$ 5,734,424	$ 6,588,483
Conversion premium	9,308,919	9,819,661	11,282,157
May only be used to offset deficits			
Donations from shareholders	9,463	8,626	8,514
Recognition of changes in ownership interests in subsidiaries (2)	33	33	3
Changes in equity of associates recognized using the equity method	13,981	13,981	409
	$14,768,560	$15,576,725	$17,879,566

1) The capital surplus may be used to offset deficits, or may be distributed as cash dividends or transferred to share capital (limited to a certain percentage of the Company's paid-in capital every year) when the Company has no deficits.

2) Such capital surplus represents the effects of equity transactions recognized due to changes in the associates' equity when the Company did not actually acquire or dispose of the associates' shares, or adjustments to the capital surplus of the associates recognized using the equity method.

c. Retained earnings and dividend policy

In accordance with the profit distribution policy as set forth in the Company's Articles of Incorporation, profit distribution or offsetting of deficits shall be made at the end of every six months of a fiscal year. When the Company makes profits in the first half of a fiscal year, the profits shall be appropriated as follows:

1) To pay taxes,
2) To offset cumulative deficits,
3) To estimate compensation of employees and remuneration of directors,
4) To set aside 10% of the profits as legal reserve, unless the cumulative legal reserve equals the Company's paid-in capital,
5) To set aside or reverse special reserves in accordance with the pertinent laws or operational needs, and
6) The Company's Board of Directors shall propose a plan to distribute any remaining profits together with cumulative retained earnings and retained earnings for the current period. For distribution in new shares, the proposal shall be approved at a shareholders' meeting. For distribution in cash, it shall be approved at the Board of Directors.

When the Company makes profits in a fiscal year, the profits shall be appropriated as follows:

1) To pay taxes,
2) To offset cumulative deficits,
3) To set aside 10% of the profits as legal reserve, unless the cumulative legal reserve equals the Company's paid-in capital,
4) To set aside or reverse special reserves in accordance with the pertinent laws or operational needs, and
5) The Company's Board of Directors shall propose a plan to distribute any remaining profits together with cumulative retained earnings and retained earnings for the current period. For distribution in new shares, the proposal shall be approved at a shareholders' meeting.

The Company is still in the growth stage. Looking forward, it will continue to monitor changes in the economic environment in order to achieve sustainable operations and long-term development. When proposing the appropriation of earnings, the Board of Directors shall focus on stability and growth of dividends; cash dividends shall not be less than 10% of total dividends, while stock dividends may be distributed under the circumstances that cash dividends per share is less than NT$0.5.

With regard to the policies on distributing the compensation of employees and remuneration of directors, please refer to "Compensation of employees and remuneration of directors" in Note 26(h).

The legal reserve may be used to offset deficits. Where there is no deficit and the legal reserve has exceeded 25% of the Company's paid-in capital, the excess may be transferred to capital or distributed in cash.

The Company's semi-annual appropriations of earnings for the year 2024 and cash dividends per share were respectively approved by the Board of Directors as follows:

	July 1 to December 31, 2024	January 1 to June 30, 2024
Board resolution date	April 16, 2025	November 6, 2024
Legal reserve	$ 519,092	$ 802,413
Special reserve (reversal)	$ -	($ 2,669,364)
Cash dividends	$ 5,193,161	$ 5,102,731
Cash dividends per share (NT$)	$ 8	$ 7.5

Distribution of the above cash dividends was resolved by the Board of Directors. The other earnings appropriations were approved at the General Meeting of Shareholders on May 27, 2025.

The Company's semi-annual appropriations of earnings for the year 2025 and cash dividends per share were respectively approved by the Board of Directors as follows:

	July 1 to December 31, 2025	January 1 to June 30, 2025
Board resolution date	April 8, 2026	November 6, 2025
Special reserve (reversal)	($ 10,666,316)	$ 14,521,192
Cash dividends	$ 3,833,102	$ 1,871,007
Cash dividends per share (NT$)	$ 7	$ 3.16

Distribution of the above cash dividends was approved by the Board of Directors, with the remaining appropriations of earnings pending resolution of the General Meeting of Shareholders to be held on May 27, 2026.

d. Other equity

1) Exchange differences from translating the financial statements of foreign operations

	January 1 to March 31, 2026	January 1 to March 31, 2025
Opening balance	$ 1,193,327	$ 7,508,967
Exchange differences from translating the financial statements of foreign operations	3,080,113	2,124,588
Share of differences of associates accounted for using the equity method	7,184	10,236
Ending balance	$ 4,280,624	$ 9,643,791

2) Unrealized valuation gain (loss) on financial assets at FVTOCI

	January 1 to March 31, 2026	January 1 to March 31, 2025
Opening balance	($ 5,048,203)	($ 6,589,128)
Unrealized gain (loss)		
Equity instruments	693,829	(456,455)
Debt instruments	(905,842)	2,467,902
Share of differences of associates accounted for using the equity method	(537)	(301)
Reclassification adjustment		
Disposal of debt instruments	219	9,929
Cumulative gain (loss) from disposing of equity instruments transferred to retained earnings	(3,953)	(57,110)
Ending balance	($ 5,264,487)	($ 4,625,163)

e. Non-controlling interests

	January 1 to March 31, 2026	January 1 to March 31, 2025
Opening balance	$ 3,350,355	$ -
Current-period net profit	51,050	72,227
Acquisition of non-controlling interests of subsidiaries (Note 29)	-	3,493,058
Purchase of non-controlling interests of subsidiaries	(10,500)	(26,211)
Changes in subsidiaries' equity	-	7
Ending balance	$ 3,390,905	$ 3,539,081

f. Treasury shares

Purpose of buy-back	Shares cancelled (in thousands of shares)
Number of shares at January 1, 2025	8,810
Increase in the current period	22,409
Number of shares at March 31, 2024	31,219
Number of shares at January 1, 2026	4,301
Increase in the current period	40,282
Decrease in current period	30,800
Number of shares at March 31, 2026	13,783

On December 20, 2024, the Company's Board of Directors resolved to buy back 34,000 thousand shares from December 21, 2024 to February 20, 2025 at a price ranging from NT$126.00 to NT$296.40 per share in order to maintain the Company's credibility and protect shareholders' equity. The Company will continue to buy back shares when the market price falls below the lower limit of the price range. At the end of the exercise period, the Company had repurchased 31,219 thousand shares at a total cost of NT$6,089,572 thousand.

On April 16, 2025, the Company's Board of Directors resolved to buy back 33,000 thousand shares from April 17, 2025 to June 16, 2025 at a price ranging from NT$138 to NT$307 per share in order to maintain the Company's credibility and protect shareholders' equity. The Company will continue to buy back shares when the market price falls below the lower limit of the price range. At the end of the exercise period, the Company had repurchased 25,476 thousand shares at a total cost of NT$5,374,746 thousand.

On October 17, 2025, the Company's Board of Directors resolved to buy back 31,500 thousand shares from October 18, 2025 to December 17, 2025 at a price ranging from NT$125.5 to NT$277.5 per share in order to maintain the Company's credibility and protect shareholders' equity. The Company will continue to buy back shares when the market price falls below the lower limit of the price range. At the end of the exercise period, the Company had repurchased 31,500 thousand shares at a total cost of NT$6,340,784 thousand.

On December 13, 2025, the Company's Board of Directors resolved to buy back 30,800 thousand shares from December 24, 2025 to February 23, 2026 at a price ranging from NT$136.5 to NT$299 per share in order to maintain the Company's credibility and protect shareholders' equity. The Company will continue to buy back shares when the market price falls below the lower limit of the price range. At the end of the exercise period, the Company had repurchased 30,800 thousand shares at a total cost of NT$6,328,755 thousand.

On March 11, 2026, the Company's Board of Directors resolved to buy back 28,400 thousand shares from March 12, 2026 to May 11, 2026 at a price ranging from NT$127.5 to NT$295 per share in order to maintain the Company's credibility and protect shareholders' equity. The Company will continue to buy back shares when the market price falls below the lower limit of the price range. At the end of the exercise period, the Company had repurchased 22,548 thousand shares at a total cost of NT$4,321,990 thousand.

In accordance with the Securities and Exchange Act, treasury shares shall not exceed 10% of the Company's issued and outstanding shares, and the total amount of treasury shares shall not exceed total retained earnings plus additional paid-in capital and realized capital reserve.

In accordance with the Securities and Exchange Act, the Company shall neither pledge treasury shares nor exercise shareholders' rights on these shares, such as the rights to dividends and to vote.

25. REVENUE

	January 1 to March 31, 2026	January 1 to March 31, 2025
Revenue from contracts with customers		
Metal casing and interior structured parts	$ 3,183,965	$ 3,720,015
Medical consumables	556,476	582,171
Others	25,152	31,181
Rental income	7,259	8,011
Revenue from the rendering of services	1,093	8,910
	$ 3,773,945	$ 4,350,288

a. Contract information

The Group sells metal casing to brand customers. All goods are sold at respective fixed prices as agreed in the contracts.

b. Contract balances

	March 31, 2026	December 31, 2025	March 31, 2025	January 1, 2025
Trade receivables				
Gross Carrying Amount	$3,488,642	$4,072,787	$5,574,345	$5,648,925
Less: allowance for impairment loss	(19,068)	(8,309)	(8,311)	(8,309)
	$3,469,574	$4,064,478	$5,566,034	$5,640,616
Contract liabilities - current				
Sale of goods	$ 76,434	$ 98,695	$ 56,774	$ 26,130

26. NET PROFIT

a. Interest income

	January 1 to March 31, 2026	January 1 to March 31, 2025
Bank deposits	$ 814,519	$ 1,070,339
Investments in debt instruments at FVTOCI	882,039	944,708
Repurchase agreements	847	238
	$ 1,697,405	$ 2,015,285

b. Other income

	January 1 to March 31, 2026	January 1 to March 31, 2025
Government grants	$ 3,092	$ 1,202
Recycling income	3,019	6,907
Dividend income	4	5
Other income	5,148	4,071
	$ 11,263	$ 12,185

c. Other gains (losses)

	January 1 to March 31, 2026	January 1 to March 31, 2025
Gains (losses) on financial assets at FVTPL	($ 59,202)	$ 49,985
Losses on disposal of investments in debt instruments at FVTOCI	(219)	(9,929)
Gains on disposal of investments accounted for using the equity method	-	480,772
Others	(2,971)	194,490
	($ 62,392)	$ 715,318

d. Interest expense

	January 1 to March 31, 2026	January 1 to March 31, 2025
Interest on bank loans	$ 300,259	$ 243,905
Interest on lease liabilities	2,268	2,116
	$ 302,527	$ 246,021

e. Depreciation and amortization

	January 1 to March 31, 2026	January 1 to March 31, 2025
Depreciation by function		
Operating costs	$ 316,569	$ 319,240
Operating expenses	63,503	71,314
	$ 380,072	$ 390,554
Amortization by function		
Operating costs	$ 2,245	$ 2,344
Operating expenses	27,473	28,808
	$ 29,718	$ 31,152

f. Operating expenses directly related to investment properties

	January 1 to March 31, 2026	January 1 to March 31, 2025
Direct operating expenses from investment properties generating rental income	$ 1,303	$ 1,157

g. Employee benefits

	January 1 to March 31, 2026	January 1 to March 31, 2025
Short-term employee benefits	$ 1,740,272	$ 1,627,806
Retirement benefits		
Defined contribution plan	125,085	101,312
Defined benefit plan (Note 23)	1,036	875
	126,121	102,187
	$ 1,866,393	$ 1,729,993
By function		
Operating costs	$ 1,437,246	$ 1,369,192
Operating expenses	429,147	360,801
	$ 1,866,393	$ 1,729,993

h. Compensation of employees and remuneration of directors

The Company accrued the compensation of employees and remuneration of directors at the rates of no less than 1% and no higher than 1%, respectively, of net profit before income tax. In accordance with the amendment to the Securities and Exchange Act in August 2024, the Company resolved at the 2025 shareholders’ meeting to amend its Articles of Incorporation to specify that no less than 1% of the annual pre-tax profit, before deducting employees' and directors' remuneration, shall be allocated as employees' remuneration. Of this amount, at least 10% shall be allocated to entry-level employees. Estimated employee compensation (including entry-level employees) and director remuneration from January 1 to March 31 in 2026 and 2025 were as follows:

Accrual rate

	January 1 to March 31, 2026	January 1 to March 31, 2025
Compensation of employees	1.00%	1.63%
Remuneration of directors	0.40%	0.19%

Amount

	January 1 to March 31, 2026	January 1 to March 31, 2025
Compensation of employees	$ 18,111	$ 61,744
Remuneration of directors	7,200	7,200

If there are any further changes in the amounts after the publication of the annual consolidated financial statements, the difference will be treated as changes in accounting estimates and adjusted and recorded in the following year.

The compensation of employee compensation and director remuneration for the years ended 2025 and 2024, approved by the Company's Board of Directors on March 3, 2026 and February 24, 2025, respectively, were as follows:

	2025	2024
	Cash	Cash
Compensation of employees	$ 170,505	$ 166,500
Remuneration of directors	$ 28,800	$ 18,200

There was no difference between the actual amount of employee compensation and director remuneration distributed in 2025 and 2024 and the amount recognized in the consolidated financial statements for the years ended December 31, 2025 and 2024.

Information on the compensation of employees and remuneration of directors resolved by the Company's Board of Directors is available on the Market Observation Post System website of the Taiwan Stock Exchange.

i. Foreign currency exchange gains (losses), net

	January 1 to March 31, 2026	January 1 to March 31, 2025
Total foreign currency exchange gains	$ 1,794,727	$ 1,463,817
Total foreign currency exchange losses	(1,572,802)	(845,699)
Net income (loss)	$ 221,925	$ 618,118

27. TAXATION

a. Income tax recognized in profit or loss

Major components of income tax expense were as follows:

	January 1 to March 31, 2026	January 1 to March 31, 2025
Current tax		
Tax recognized in the current period	$ 603,537	$ 481,997
Adjustments for prior years	(1,437)	-
	602,100	481,997
Deferred tax		
Tax recognized in the current period	(286,143)	417,845
Adjustments for prior years	-	125,626
	(286,143)	543,471
	$ 315,957	$ 1,025,468

The applicable corporate income tax rate adopted by the Group is 20%; the tax rate applicable to the subsidiaries in China is 25%. The tax amounts incurred in other jurisdictions is calculated based on the applicable tax rate of each relevant jurisdiction.

b. Income tax determination

The corporate income taxes declared by the Company and its subsidiaries Ke Yue, Yi Sheng, Yi De, Catcher Medtech, Yi Fa, Yih Chuan, Yi Zhu, Coforce Medical and Pacific Hospital Supply Co., Ltd. have been approved by the tax collection authority up to the year of 2024.

28. EARNINGS PER SHARE

The earnings and weighted average number of ordinary shares outstanding in the computation of earnings per share were as follows:

Net profit

	January 1 to March 31, 2026	January 1 to March 31, 2025
Profit attributable to owners of the Company	$ 1,484,484	$ 2,894,936

Number of shares

In thousand shares

	January 1 to March 31, 2026	January 1 to March 31, 2025
Weighted average number of ordinary shares in computation of basic earnings per share	565,038	653,907
Potential dilution of ordinary shares:		
Compensation of employees	713	794
Weighted average number of ordinary shares in computation of diluted earnings per share	565,751	654,701

The Company may settle compensation paid to employees in cash or shares; therefore, the Company may assume that the compensation will be settled in shares and include the potentially dilutive ordinary shares in the weighted average number of shares outstanding when computing the diluted earnings per share. When computing the diluted earnings per share before determining the compensation paid to employees in shares in the following year, the Group shall continuously take into consideration the potential dilution of the ordinary shares.

29. BUSINESS COMBINATION

a. Acquisition of subsidiary

	Principal Business Activities	Acquisition date	Ownership Interest with Voting Rights/Percentage of Ownership Acquired (%)	Consideration Transferred
Pacific Hospital Supply Co., Ltd.	Manufacturing and selling medical devices	January 1, 2025	31.54	$ 2,232,652

b. Consideration transferred

The consideration transferred is measured at its fair value on the acquisition date.

c. Assets acquired and liabilities assumed on the acquisition date

	Pacific Hospital Supply Co., Ltd.
Current assets	
Cash and cash equivalents	$ 740,071
Trade receivables and other receivables	271,413
Inventories	338,154
Others	404,355
Non-current assets	
Property, plant and equipment	3,044,959
Right-of-use assets	413,147
Investment properties	180,065
Intangible assets	1,031,442
Deferred tax assets	8,793
Others	44,311
Current liabilities	
Trade payables and other payables	(412,076)
Others	(104,153)
Non-current liabilities	
Deferred tax liabilities	(439,616)
Others	(418,432)
	$ 5,102,433

d. Non-controlling interests

The non-controlling interests of Pacific Hospital Supply Co., Ltd. were measured at the proportionate share of the recognized amount of the acquiree’s identifiable net assets.

e. Goodwill from the acquisition

	Pacific Hospital Supply Co., Ltd.
Consideration transferred	$ 2,232,652
Plus: Non-controlling interests	3,493,058
Less: Fair value of identifiable net assets acquired	(5,102,433)
Goodwill from the acquisition	$ 623,277

f. Impact of the retrospective restatement on the financial statements for 2025 Q1.

The Group has completed a number of investment and acquisition transactions during different comparative periods, including the purchase of operating assets, financial asset reclassifications as investments using the equity method, and staged acquisition of subsidiary. Relevant transactions have been allocated or the cost of investments measured according to their nature, and the acquisition price allocation report has been completed. The restatement of information is as follows:

Effect on assets, liabilities, and equity items as of March 31, 2025

Item	Amount Before Restatement	Operating Assets Acquired (Note 18)	Corporate Merger (Note 13)	Significant Influence Acquired (Note 14)	Amount After Restatement
Investments accounted for using the equity method	$ 3,970,016	$ -	$ -	($ 8,542)	$ 3,961,474
Property, plant and equipment	$ 13,349,840	$ -	$ 1,470,273	$ -	$ 14,820,113
Investment properties	$ 1,255,443	$ -	$ 88,674	$ -	$ 1,344,117
Intangible assets	$ 22,685	$ 59,696	$ 1,005,819	$ -	$ 1,088,200
Goodwill	$ 1,471,846	($ 52,122)	($ 681,358)	$ -	$ 738,366
Deferred tax assets	$ 2,645,962	$ 156	$ -	$ -	$ 2,646,118
Deferred tax liabilities	$ 6,133,187	$ 12,095	$ 430,873	$ -	$ 6,576,155
Non-controlling interests	$ 2,078,094	$ -	$ 1,460,987	$ -	$ 3,539,081

Effect on comprehensive income from January 1 to March 31, 2025

Item	Amount Before Restatement	Amount Affected	Amount after Restatement
General and administrative expenses	$ 290,657	$ 35,606	$ 326,263
Share of profits (losses) from associates accounted for using the equity method	$ 58,213	($ 8,542)	$ 49,671
Taxation	$ 1,030,395	($ 4,927)	$ 1,025,468
Effect of net profit for the current period	$ 3,006,384	($ 39,221)	$ 2,967,163
Effect of net profit attributable to:			
Owners of the Company	$ 2,916,295	($ 21,359)	$ 2,894,936
Non-controlling interests	90,089	(17,862)	72,227
	$ 3,006,384	($ 39,221)	$ 2,967,163
Effect of total comprehensive income attributable to:			
Owners of the Company	$ 7,072,194	($ 21,359)	$ 7,050,835
Non-controlling interests	90,089	(17,862)	72,227
	$ 7,162,283	($ 39,221)	$ 7,123,062

(Continued)

(Continued from previous page)

Item	Amount Before Restatement	Amount Affected	Amount After Restatement
Effect on earnings per share			
Basic earnings per share	$ 4.46	($ 0.03)	$ 4.43
Diluted earnings per share	$ 4.45	($ 0.03)	$ 4.42

30. EQUITY TRANSACTIONS WITH NON-CONTROLLING INTERESTS

From January 1 to March 31, 2026 and 2025, the Group acquired 251 thousand common shares and 637 thousand common shares of its subsidiary, Pacific Hospital Supply Co., Ltd., on the open market, respectively.

The above transaction did not alter the Group’s control over the subsidiary, thus, it was accounted for as an equity transaction.

	January 1 to March 31, 2026	January 1 to March 31, 2025
	Minority Interest Acquired	Minority Interest Acquired
Consideration paid	($ 20,267)	($ 60,153)
Amount of non-controlling interests to be reclassified, calculated based on the relative change in ownership interests of the subsidiary’s net asset carry amount	10,500	26,211
Difference from equity transaction	($ 9,767)	($ 33,942)
Difference adjustment of equity transaction		
Unappropriated earnings	($ 9,767)	($ 33,942)

31. CAPITAL RISK MANAGEMENT

The Group manages its capital in a manner to ensure that it has sufficient and necessary financial resources as well as business plans to fund its working capital in need, capital expenditure, research and development activities, debt repayment and dividend distribution over the next 12 months.

32. FINANCIAL INSTRUMENTS

a. Financial instruments not measured at fair value

The carrying amounts of financial instruments not measured at fair value are recognized to reasonably approximate their fair value; these financial instruments include cash and cash equivalents, financial assets at amortized cost, accounts receivable, other receivables, refundable deposits, short-term borrowings, accounts payable, other payables, and guarantee deposits received.

b. Financial instruments measured at fair value on a recurring basis

1) Fair value hierarchy

March 31, 2026

	Level 1	Level 2	Level 3	Total
Financial assets measured at FVTPL				
Foreign listed stocks	$ 554	$ -	$ -	$ 554
Foreign non-listed stocks	-	-	34,038	34,038
Beneficiaries certificates	674,543	-	-	674,543
Private equity funds	-	-	2,914,085	2,914,085
Limited partnerships	-	-	250,246	250,246
Simple Agreement for Future Equity (SAFE)	-	-	26,072	26,072
	$ 675,097	$ -	$ 3,224,441	$ 3,899,538
Financial assets measured at FVTOCI				
Investments in equity instruments				
- Domestic listed stocks	$ 6,876,279	$ -	$ -	$ 6,876,279
- Domestic non-listed stocks	-	-	303,521	303,521
- Foreign listed stocks	2,689,973	-	-	2,689,973
- Limited partnerships	-	-	1,765,145	1,765,145
Investments in debt instruments				
- Bonds	-	80,942,330	-	80,942,330
	$ 9,566,252	$80,942,330	$ 2,068,666	$92,577,248

December 31, 2025

	Level 1	Level 2	Level 3	Total
Financial assets measured at FVTPL				
Foreign listed stocks	$ 604	$ -	$ -	$ 604
Foreign non-listed stocks	-	-	33,437	33,437
Beneficiaries certificates	644,757	-	-	644,757
Private equity funds	-	-	2,817,509	2,817,509
Limited partnerships	-	-	249,877	249,877
Simple Agreement for Future Equity (SAFE)	-	-	26,072	26,072
	$ 645,361	$ -	$ 3,126,895	$ 3,772,256
Financial assets measured at FVTOCI				
Investments in equity instruments				
- Domestic listed stocks	$ 6,749,002	$ -	$ -	$ 6,749,002
- Domestic non-listed stocks	-	-	302,340	302,340
- Foreign listed stocks	2,094,660	-	-	2,094,660
- Limited partnerships	-	-	1,548,752	1,548,752
Investments in debt instruments				
- Bonds	-	81,716,922	-	81,716,922
	$ 8,843,662	$ 81,716,922	$ 1,851,092	$ 92,411,676

March 31, 2025

	Level 1	Level 2	Level 3	Total
Financial assets measured at FVTPL				
Foreign listed stocks	$ 597	$ -	$ -	$ 597
Foreign non-listed stocks	-	-	35,325	35,325
Beneficiaries certificates	505,631	-	-	505,631
Private equity funds	-	-	2,707,901	2,707,901
Limited partnerships	-	-	252,819	252,819
	$ 506,228	$ -	$ 2,996,045	$ 3,502,273
Financial assets measured at FVTOCI				
Investments in equity instruments				
- Domestic listed stocks	$ 5,365,997	$ -	$ -	$ 5,365,997
- Domestic non-listed stocks	-	-	248,604	248,604
- Foreign listed stocks	986,925	-	-	986,925
- Limited partnerships	-	-	2,188,208	2,188,208
Investments in debt instruments				
- Bonds	-	88,272,201	-	88,272,201
	$ 6,352,922	$88,272,201	$ 2,436,812	$97,061,935

There were no transfers between Level 1 and Level 2 fair value measurements during the period from January 1 to March 31, 2026 and 2025.

2) Reconciliation of Level 3 fair value measurements of financial instruments

January 1 to March 31, 2026

Financial Assets	Equity Instruments at FVTPL	Equity Instruments at FVTOCI	Total
Opening balance	$ 3,126,895	$ 1,851,092	$ 4,977,987
Purchases	143,959	158,217	302,176
Recognized in profit or loss (other gains and losses)	(84,745)	-	(84,745)
Recognized in other comprehensive income (unrealized valuation gain/loss on financial assets at FVTOCI)	-	29,637	29,637
Return of capital contribution	(13,302)	-	(13,302)
Effects of foreign currency exchange differences	51,634	29,720	81,354
Ending balance	$ 3,224,441	$ 2,068,666	$ 5,293,107

January 1 to March 31, 2025

Financial Assets	Equity Instruments at FVTPL	Equity Instruments at FVTOCI	Total
Opening balance	$ 2,523,403	$ 2,637,244	$ 5,160,647
Purchases	383,618	-	383,618
Recognized in profit or loss (other gains and losses)	58,791	-	58,791
Recognized in other comprehensive income (unrealized valuation gain/loss on financial assets at FVTOCI)	-	(228,874)	(228,874)
Effects of foreign currency exchange differences	30,233	28,442	58,675
Ending balance	$ 2,996,045	$ 2,436,812	$ 5,432,857

3) Valuation techniques and assumptions used for Level 2 fair value measurement

The fair values of foreign corporate bonds and government bonds are measured based on open market quotations provided by the third party.

4) Valuation techniques and inputs used for Level 3 fair value measurement

The fair values of non-listed domestic equity securities, limited partnerships, and private equity securities are estimated using the market approach or based on the most recent net worth of the investees. When the market approach is adopted, the selling prices of comparable companies are used for comparison, analysis and adjustment to derive the fair value of the investees. The fair value of private equity funds is estimated using the asset approach.

c. Categories of financial instruments

	March 31, 2026	December 31, 2025	March 31, 2025
Financial assets			
Equity instruments measured at FVTPL			
Mandatorily measured at FVTPL	$ 3,899,538	$ 3,772,256	$ 3,502,273
Financial assets measured at amortized cost (Note 1)	97,140,694	101,181,673	105,684,192
Financial assets measured at FVTOCI			
Investments in equity instruments	11,634,918	10,694,754	8,789,734
Investments in debt instruments	80,942,330	81,716,922	88,272,201
Financial liabilities			
Financial liabilities measured at amortized cost (Note 2)	72,361,238	68,851,979	54,023,156

Note 1: The balance comprises financial assets measured at amortized cost including cash and cash equivalents, note receivables, trade receivables, other receivables, and refundable deposits.

Note 2: The balance comprises financial liabilities measured at amortized cost, including short-term borrowings, note payables, trade payables, other payables, and guarantee deposits received (recognized as other current liabilities and non-current liabilities).

d. Objectives and policies of financial risk management

The Group’s major financial instruments include equity and debt investments, trade receivables, trade payables, borrowings, and lease liabilities. The Group’s Finance Department serves various business units, coordinates access to domestic and international financial markets, and monitors as well as manages the financial risks relating to operations based on the internal risk reports which analyze exposures by degree and magnitude of risks. These risks include market risk (including foreign currency risk, interest rate risk and other price risk), credit risk and liquidity risk.

The Group’s material financial activities are reviewed by the Board of Directors in accordance with relevant regulations and internal control rules. Policy compliance and risk exposure are constantly reviewed by internal auditors. The Group does not trade financial instruments (including derivative financial instruments) for speculative purposes.

1) Market risk

The Group’s operational activities are exposed primarily to the financial risks of movement in foreign currency exchange rates (see (a) below), interest rates (see (b) below) and other price risks (see (c) below).

There has been no change to the Group’s exposure to the market risks of financial instruments or the manner in which these risks were managed and measured.

a) Exchange rate risk

Engaging in foreign currency-denominated sales and purchases, the Group is exposed to exchange rate risk.

Refer to Note 36 for the carrying amounts of the Group’s non-functional currency-denominated monetary assets and monetary liabilities (including the non-functional currency-denominated monetary items eliminated on consolidation) at the end of the reporting period.

Sensitivity analysis

The Group is mainly affected by exchange rate volatility of the US dollar (USD).

The following table details the Group's sensitivity to a 1% increase and decrease in the functional currency against relevant foreign currencies. The sensitivity analysis only applies to outstanding foreign currency-denominated monetary items. A positive number below indicates an increase in profit before income tax that would result from the depreciation of the NTD by 1% against the relevant foreign currencies. When the NTD appreciates by 1% against the relevant foreign currencies, there would be an equal and opposite impact on profit before income tax, with the balances below turning to negative.

	USD impact	
	January 1 to March 31, 2026	**January 1 to March 31, 2025**
Profit (loss)	$ 316,038	$ 426,610

The aforementioned foreign currency-denominated monetary assets or liabilities are mainly the Group's outstanding exposure to USD-denominated cash and cash equivalents, financial assets at amortized cost, as well as receivables and payables, without cash flow hedge, as at the end of the reporting period.

The decrease in the Group's sensitivity to the exchange rates of USD is mainly due to the decrease in the USD-denominated net assets. The Group's management believes that the sensitivity analysis cannot represent the inherent risk of exchange rates, because the foreign currency exposure at the reporting date does not reflect the mid-term risk exposure, where the USD-denominated sales revenue would vary along with customer orders and investment assets.

b) Interest rate risk

The Group was exposed to interest rate risk because entities in the Group borrowed funds at both fixed and floating interest rates. The Group manages interest rate risk by maintaining an appropriate mix of assets and liabilities at both fixed and floating interest rates.

The carrying amounts of the Group's financial assets and liabilities with exposure to interest rates at the end of the reporting period were as follows:

	March 31, 2026	**December 31, 2025**	**March 31, 2025**
Fair value related interest rate risk			
Financial assets	$166,063,400	$164,149,519	$179,380,379
Financial liabilities	1,479,750	5,233,400	5,377,231
Cash flow related interest rate risk			
Financial assets	6,734,820	13,472,144	6,950,875
Financial liabilities	65,490,000	57,400,000	43,300,000

Sensitivity analysis

The sensitivity analysis below was conducted based on the Group's exposure to interest rates for non-derivative instruments at the end of the reporting period. Analysis for the liabilities with floating interest rates was conducted assuming that the amount of the outstanding liabilities at the reporting date was outstanding for the reporting period.

If interest rates move 10 basis points higher/lower with all other variables held constant, the Group's profit before income tax for the period from January 1 to March 31 in 2026 and 2025 would decrease/increase by NT$14,689 thousand and NT$9,087 thousand, respectively. The change would have been mainly attributable to the Group's exposure to interest rate risk associated with the cash flow from its variable-rate bank borrowings.

c) Other price risks

The Group was exposed to equity price risk due to its investment in listed equity securities and beneficial certificates of mutual funds. The Group has managed the underlying risks via holding different investment portfolios and asset allocation.

Sensitivity analysis

The sensitivity analysis below is conducted based on the Group's exposure to equity price risks at the end of the reporting period.

If the equity price increases/decreases by 1%, the Group's profit before tax for the period from January 1 to March 31 in 2026 and 2025 would increase/decrease by NT$38,995 thousand and NT$35,023 thousand, respectively, due to the increase/decrease in the fair value of financial assets measured at fair value through profit and loss (FVTPL), and its other comprehensive profit and loss before tax for the period from January 1 to March 31 in 2026 and 2025 would increase/decrease by NT$116,349 thousand and NT$87,897 thousand, respectively, due to the increase/decrease in the fair value of financial assets measured at fair value through other comprehensive income (FVTOCI).

2) Credit risk

Credit risk refers to the risk that a counterparty defaults in its contractual obligations and results in financial losses to the Group. As at the balance sheet date, the maximum credit risk exposure of the Group due to the failure of a counterparty to fulfill obligations is mainly the carrying amount of financial assets recognized in the consolidated balance sheets.

The Group's transaction counterparties are all corporate organizations with good credit; hence, there is no significant credit risk expected. The Group also constantly evaluates the financial status of its trade receivables customers.

Trade receivables with significantly concentrated credit risk were as follows:

	March 31, 2026		December 31, 2025		March 31, 2025	
	Amount	%	Amount	%	Amount	%
Company A	$ 957,708	27	$ 901,984	22	$ 553,264	16
Company B	752,694	22	819,267	20	2,146,644	39
Company C	509,054	15	401,907	10	602,184	11
Company D	237,970	7	445,138	11	-	-
Company E	182,820	5	505,619	12	281,787	6
Company F	-	-	-	-	876,608	16

3) Liquidity risk

The Group manages liquidity risk by maintaining an adequate level of cash and cash equivalents to finance its operations and mitigate the impact of cashflow fluctuation. Management monitors the utilization of bank facilities and ensures to comply with the terms of loan covenants.

The Group's operating funds and bank facilities are deemed sufficient for future operations; therefore, there is no liquidity risk where the Group is unable to raise funds to fulfill its contractual obligations.

a) Liquidity and interest rate risk for non-derivative financial liabilities

The remaining contractual maturity for the Group's non-derivative financial liabilities is analyzed using the undiscounted cash flows of financial liabilities (including both principal and estimated interest) based on the earliest date on which the Group would be required to pay. Therefore, the bank loans with a repayment on demand clause are included in the earliest time band regardless of the probability that the banks would choose to exercise their rights. The maturity analysis for other non-derivative financial liabilities is conducted based on the agreed repayment dates.

Where interest cash flows are paid at floating rates, the undiscounted interest is derived based on the yield curve at the balance sheet date.

March 31, 2026

	Less than 3 months	3 months-1 year	1-5 Years	More than 5 years
Non-derivative financial liabilities				
Non-interest bearing liabilities	$ 4,731,882	$ 1,201,368	$ 13,879	$ -
Lease liabilities	12,530	18,187	85,608	589,071
Variable interest rate instruments	60,901,581	4,730,000	-	-
Fixed interest rate instruments	101,143	835,702	-	-
	$65,747,136	$ 6,785,257	$ 99,487	$ 589,071

Maturity analysis of the aforementioned lease liabilities:

	Less than 1 year	1-5 years	5-10 years	10-15 years	15-20 years	More than 20 years
Lease liabilities	$ 30,717	$ 85,608	$ 91,039	$113,056	$ 91,039	$293,937

December 31, 2025

	Less than 3 months	3 months-1 year	1-5 years	More than 5 years
Non-derivative financial liabilities				
Non-interest bearing liabilities	$ 7,244,804	$ 1,385,859	$ 13,879	$ -
Lease liabilities	7,398	25,467	86,438	592,371
Variable interest rate instruments	29,968,708	27,500,000	-	-
Fixed interest rate instruments	2,254,216	2,457,498	-	-
	$ 39,475,126	$ 31,368,824	$ 100,317	$ 592,371

Maturity analysis of the aforementioned lease liabilities:

	Less than 1 Year	1-5 years	5-10 years	10-15 years	15-20 years	More than 20 years
Lease liabilities	$ 32,865	$ 86,438	$ 91,039	$113,056	$ 91,039	$297,237

March 31, 2025

	Less than 3 months	3 months-1 year	1-5 years	More than 5 years
Non-derivative financial liabilities				
Non-interest bearing liabilities	$ 4,975,271	$ 919,768	$ 15,012	$ -
Lease liabilities	11,025	17,156	75,230	602,595
Variable interest rate instruments	43,404,541	-	-	-
Fixed interest rate instruments	538,467	4,326,052	-	-
	$48,929,304	$ 5,262,976	$ 90,242	$ 602,595

Maturity analysis of the aforementioned lease liabilities:

	Less than 1 year	1-5 years	5-10 years	10-15 years	15-20 years	More than 20 years
Lease liabilities	$ 28,181	$ 75,230	$ 91,124	$113,142	$ 91,124	$307,205

Where variable interest rates differ from the interest rates estimated at the end of the reporting period, the carry amounts of the aforementioned variable interest rate instruments for both non-derivative financial assets and liabilities could change.

b) Bank facilities

	March 31, 2026	December 31, 2025	March 31, 2025
Unsecured bank facilities			
Amount used	$ 58,532,594	$ 62,096,301	$ 45,680,707
Amount unused	39,356,710	39,497,216	58,669,353
	$ 97,889,304	$101,593,517	$104,350,060
Secured bank facilities			
Amount used	$ 7,900,000	$ -	$ 2,450,260
Amount unused	24,800,000	35,000,000	21,200,000
	$ 32,700,000	$ 35,000,000	$ 23,650,260

33. TRANSACTIONS WITH RELATED PARTIES

Transactions, account balance, income and expense, as well as gains and losses between the Company and its subsidiaries (which are related parties of the Company), have been eliminated on consolidation without being disclosed in this note. Unless otherwise disclosed in other notes, the transactions between the Group and related parties were as follows:

Compensation of key management personnel

	January 1 to March 31, 2026	January 1 to March 31, 2025
Short-term employee benefits	$ 48,648	$ 42,257
Retirement benefits	12,135	9,151
	$ 60,783	$ 51,408

The remuneration of directors and key management personnel are determined by the remuneration committee with due regard to industry practice, the performance of individuals and the Group, and reasonableness associated with future risks.

34. PLEDGED ASSETS

Assets provided as collateral for financing loans were as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Restricted bank deposits (financial assets measured at amortized cost - current)	$ 4,015,487	$ -	$ 3,020,155

35. MATERIAL CONTINGENT LIABILITIES AND UNRECOGNIZED CONTRACTUAL COMMITMENTS

In addition to those disclosed in other notes, material commitments and contingent liabilities of the Group as of the balance sheet date were as follows:

Unrecognized commitments of the Group

	March 31, 2026	December 31, 2025	March 31, 2025
Acquisition of property, plant and equipment	$ 566,507	$ 947,381	$ 254,432
Acquisition of inventories	$ 164,885	$ 238,023	$ 151,332

36. FOREIGN CURRENCY ASSETS AND LIABILITIES WITH MATERIAL IMPACT

The information below is aggregated and presented in the foreign currencies other than the functional currencies adopted by the entities in the Group. The exchange rates disclosed are the rates used to convert the aforementioned foreign currencies into the respective functional currencies. Foreign currency assets and liabilities with material impact are as follows:

(In foreign currencies and New Taiwan dollars, all in thousands)

March 31, 2026

Foreign Currency Assets	Foreign Currency	Exchange Rate	Carrying Amount
Monetary items			
USD	$ 837,049	31.9424 (USD:NTD)	$ 26,737,383
USD	185,171	6.9194 (USD:RMB)	5,931,013
JPY	33,702,748	0.0062 (JPY: USD)	6,702,407
JPY	1,906,615	0.2005 (JPY:NTD)	382,276
EUR	667	36.7098 (EUR:NTD)	24,469
SGD	33,554	24.7973 (SGD: NTD)	832,052
USD	10,466	32.0450 (USD:NTD)	335,388
USD	22,766	6.9194 (USD:RMB)	729,202
RMB	5,738	4.6540 (RMB:NTD)	26,703
Foreign Currency Liabilities			
Monetary items			
USD	10,466	32.0450 (USD:NTD)	335,388
USD	22,766	6.9194 (USD:RMB)	729,202
RMB	5,738	4.6540 (RMB:NTD)	26,703

December 31, 2025

Foreign Currency Assets	Foreign Currency	Exchange Rate	Carrying Amount
Monetary items			
USD	$ 922,526	31.3807 (USD:NTD)	$ 28,949,478
USD	246,503	7.0288 (USD:RMB)	7,789,860
JPY	29,404,686	0.006335 (JPY: USD)	5,854,875
Foreign Currency Liabilities			
Monetary items			
USD	11,722	31.48 (USD:NTD)	369,017
USD	27,839	7.0288 (USD:RMB)	879,745

March 31, 2025

Foreign Currency Assets	Foreign Currency	Exchange Rate	Carrying Amount
Monetary items			
USD	$ 955,853	33.156 (USD:NTD)	$ 31,692,054
USD	369,723	7.1782 (USD:RMB)	12,136,488
JPY	14,236,038	0.0067 (JPY: USD)	3,146,633
JPY	1,162,912	0.2227 (JPY:NTD)	258,981
EUR	1,110	35.97 (EUR:NTD)	39,934
SGD	1,340	0.7696 (SGD:USD)	34,234
Foreign Currency Liabilities			
Monetary items			
USD	9,349	33.255 (USD:NTD)	310,897
USD	26,097	7.1782 (USD:RMB)	856,660
RMB	3,379	4.598 (RMB:NTD)	15,536

The Group is mainly exposed to the USD. The information as follows was an aggregation of the functional currencies adopted by the entities in the Group, and the exchange rates disclosed are the rates used to convert the respective functional currencies into the presentation currency. Material foreign currency exchange gains and losses (realized and unrealized) were as follows:

	January 1 to March 31, 2026		January 1 to March 31, 2025	
Functional Currency	Exchange Rate	Net Foreign Exchange Gain (Loss)	Exchange Rate	Net Foreign Exchange Gain (Loss)
USD	31.6307 (USD:NTD)	($ 116,748)	32.895 (USD:NTD)	$ 143,207
NTD	1 (NTD:NTD)	515,610	1 (NTD:NTD)	478,178
RMB	4.5511 (RMB:NTD)	(160,570)	4.584 (RMB:NTD)	(5,074)
THB	1.0059 (THB:NTD)	(16,367)	0.9724 (THB:NTD)	1,807
		$ 221,925		$ 618,118

37. SEPARATELY DISCLOSED ITEMS

a. Material transactions:

1) Loaning of funds to others. (Table 1)

2) Endorsements/guarantees provided. (Table 2)

3) Significant marketable securities held at the end of the period (excluding investments in subsidiaries and associates). (Table 3)

4) Total purchases from or sales to related parties amounting to at least NT$100 million or 20% of the Company’s paid-in capital. (Table 4)

5) Receivables from related parties amounting to at least NT$100 million or 20% of the Company’s paid-in capital. (Table 5)

6) Others: Business relationships, material transactions and the transaction amount thereof between the parent company and subsidiaries, and among subsidiaries (Table 8)

b. Information on investees. (Table 6)

c. Information on investments in Mainland China:

a) Including names, main businesses, paid-in capital, methods of investment, inward and outward remittances of funds, percentage of ownership, net profit or loss for the current period, investment profit or loss recognized, carrying amount of investment at the end of the reporting period, repatriations of investment profit or loss, and limitation of investment in the Mainland China area (Table 7)

b) Material transactions with investee companies in Mainland China as follows, either directly or indirectly through a third party, and their prices, payment terms, and unrealized gains or losses. (Tables 1, 4, 5 and 8)

   a) Purchase amount and percentage, and the closing balance and percentage of related payables.

   b) Sales amount and percentage, and the closing balance and percentage of related receivables.

   c) Amount of property transactions and the resulting profit or loss.

   d) Ending balance of endorsements, guarantees, or pledges of collateral as well as the purposes thereof.

   e) Financing – the maximum balance, ending balance, interest rate range, and the total amount of interest charged for the current period.

   f) Other transactions having a material impact on profit or loss or financial position for the current period, such as the provision or receipt of services.

38. INFORMATION ON SEGMENTS

<u>Segment income and operation results</u>

The reportable segments of the Group are identified based on management’s operational management model, using product categories and major businesses as the basis. This information is provided to the main operating decision maker to allocate resources and to evaluate the performance of segments.

The reportable segments of the Group are as follows:

Catcher Technology Co., Ltd. - Its main business is the manufacturing, processing, and sale of various alloy casings, including aluminum and magnesium alloys, molds, and land and plant leasing business.
Pacific Hospital Supply Co., Ltd.: Its main business includes the manufacturing, processing, and trading of various medical equipment, as well as the installation and piping of medical gas equipment, and the construction and trading of related equipment.

	Catcher Technology Co., Ltd.	**Pacific Hospital Supply Co., Ltd.**	**Adjustment and write-off**	**Total**
January 1 to March 31, 2026				
Revenue from external customers	$ 3,192,374	$ 581,571	$ -	$ 3,773,945
Inter-segment revenue	4,484,996	-	(4,484,996)	-
Total segment revenue	$ 7,677,370	$ 581,571	($ 4,484,996)	$ 3,773,945
Segment profit or loss	$ 126,921	$ 116,507	$ -	$ 243,428
Other non-operating revenue and expense				1,910,590
Interest expense				(302,527)
Profit before income tax				$ 1,851,491
January 1 to March 31, 2025				
Revenue from external customers	$ 3,745,751	$ 604,537	$ -	$ 4,350,288
Inter-segment revenue	2,629,265	-	(2,629,265)	-
Total segment revenue	$ 6,375,016	$ 604,537	($ 2,629,265)	$ 4,350,288
Segment profit or loss	$ 695,318	$ 132,757	$ -	$ 828,075
Other non-operating revenue and expense				3,410,577
Interest expense				(246,021)
Profit before income tax				$ 3,992,631

Segment profit or loss refers to the profit/loss of each segment, excluding the income tax expenses. The amount of measurement provided to the key operating decision maker for resource allocation and performance evaluation of departments.

The main operating decision maker of the Group makes operating decisions based on the results of each segment and has not evaluated the classification of assets and liabilities that reflect the performance of other business activities. Therefore, only the results of the reportable segments are disclosed.

Table 1

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

LOANING OF FUNDS TO OTHERS
JANUARY 1 TO MARCH 31, 2026
(In Thousands of New Taiwan Dollars)

No.	Lender	Borrower	Account	Related Parties	Highest Balance for the Period	Ending Balance	Actual Borrowing Amount	Interest Rate Range (%)	Nature of Financing	Business Transaction Amount	Reasons for Short Term Financing	Allowance for Doubtful Accounts	Collateral		Limit of Loaning of Funds to Each Borrower (Note 1)	Limit of Aggregate Amount of Loans (Note 2)
													Name	Value		
0	Catcher Technology Co., Ltd.	Topo Technology (Thailand) Co., Ltd.	Other receivables from related parties	Yes	$ 479,175	$ 479,175	$ 431,258	3.5%	For short-term financing	$ -	Operating capital	$ -	-	$ -	$ 27,833,204	$ 55,666,408
0	Catcher Technology Co., Ltd.	Xincher Precision Manufacturing Co., Ltd.	Other receivables from related parties	Yes	125,180	$ 63,890	19,167	2.6%~3.5%	For short-term financing	-	Operating capital	-	-	-	27,833,204	$ 55,666,408
1	Catcher Technology (Suqian) Co., Ltd.	Envio Technology (Suqian) Co., Ltd.	Other receivables from related parties	Yes	64,736	$ 64,736	64,736	1.5%	For short-term financing	-	Operating capital	-	-	-	695,830,095	$ 695,830,095
2	Catcher Medtech Co., Ltd.	COFORCE Medical Inc.	Other receivables from related parties	Yes	70,000	$ 70,000	70,000	2.0%	For short-term financing	-	Operating capital	-	-	-	509,148	$ 509,148

Note 1: In accordance with the provisions of the Regulations Governing Loaning of Funds, the aggregate amount of inter-company loaning of funds between overseas companies in which the Company holds, directly or indirectly, 100% of shares shall be limited to no more than 500% of the Company's net worth at the end of the period. Such loans between domestic subsidiaries shall not exceed 40% of the subsidiary's net worth at the end of the period. For the companies which the Company has business contact with, the amount of individual loans shall not exceed the amount of the most recent annual business transactions between the two parties.

Note 2: In accordance with the provisions of the Regulations Governing Loaning of Funds, the aggregate amount of inter-company loaning of funds between overseas companies in which the Company holds, directly or indirectly, 100% of shares shall be limited to no more than 500% of the Company's net worth at the end of the period. Such of loans between domestic subsidiaries shall not exceed 40% of the subsidiary's net worth at the end of the period.

Note 3: The Company's total amount of loans to others shall not exceed 40% of its net worth. For any individual company with short-term financing needs, the amount loaned shall not exceed 20% of the Company's net worth.

Note 4: The net worth as mentioned in Note 1 and 2 refers to the equity attributable to the owners of the Company on the consolidated balance sheets.

Table 2

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

ENDORSEMENTS/GUARANTEES PROVIDED
JANUARY 1 TO MARCH 31, 2026
(In Thousands of New Taiwan Dollars)

No.	Endorser/Guarantor	Endorsee/Guarantee		Limit on Endorsement/ Guarantee Provided to Each Party (Note 1)	Maximum Amount Endorsed/Guaranteed During the Period	Ending Balance of Endorsement/Guarantee	Actual Borrowing Amount	Amount Endorsed/Guaranteed by Collateral	Ratio of Accumulated Endorsement/Guarantee to Net Worth in Latest Financial Statements (%)	Aggregate Endorsement/ Guarantee Limit (Note 2)	Endorsement/Guarantee Given by Parent on Behalf of Subsidiaries	Endorsement/Guarantee Given by Subsidiaries on Behalf of Parent	Endorsement/Guarantee Given on Behalf of Companies in Mainland China
		Company Name	Relationship										
1	Nanomag International Co., Ltd.	Catcher Technology Co., Ltd.	Note 3	$ 139,166,019	$ 4,791,750	$ 4,791,750	$ 4,200,000	$ 4,791,750	3.06	$ 278,332,038	N	Y	N

Note 1: The Company’s total external endorsements/guarantees are limited to 200% of the net value of its ultimate parent company, and the endorsement/guarantee amount for one single enterprise shall not exceed 100% of the net value of the ultimate parent company of the Company.

Note 2: The aforementioned net worth refers to the equity attributable to owners of the Company as presented in the consolidated balance sheets.

Note 3: A company with more than 50% of its voting shares directly or indirectly held by the Company.

Table 3

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

SIGNIFICANT MARKETABLE SECURITIES HELD AT THE END OF THE PERIOD
MARCH 31, 2026
(NTD Thousands or Other Foreign Currencies in Thousands)

Holding Company	Type and Name of Marketable Securities	Relationship with the Issuing Company	Account	End of Period				Note
				Unit/share/value	Carrying amount	Percentage (%)	Fair value	
The Company	Private equity funds							
	Silver Lake Partners VII, L.P.	None	Financial assets at FVTPL - non-current	-	$ 491,348	0.10	$ 491,348	
Ke Yue Co., Ltd.	Listed stocks							
	Intai Technology Corp.	None	Financial assets at FVTOCI - current	3,351,000	341,802	6.62	341,802	
	Global PMX Co., Ltd.	None	As above	2,152,000	277,608	1.87	277,608	
	Highlight Tech Corp.	None	As above	3,864,000	183,154	4.09	183,154	
	Feedback Technology Corp.	None	As above	1,945,199	279,136	3.64	279,136	
	Shih Her Technologies Inc.	None	As above	2,110,206	348,184	3.39	348,184	
	Drewloong Precision, Inc.	None	As above	2,787,641	388,876	6.97	388,876	
	Beneficiaries certificates							
	Yuanta Japan Leading Enterprise Fund	None	Financial assets at FVTPL - current	10,060,362	141,247	-	141,247	
Yi De Co., Ltd.	Listed stocks							
	Intai Technology Corp.	None	Financial assets at FVTOCI - current	2,475,000	252,450	4.89	252,450	
	Global PMX Co., Ltd.	None	As above	2,129,000	274,641	1.85	274,641	
	Highlight Tech Corp.	None	As above	1,295,200	61,392	1.37	61,392	
	Feedback Technology Corp.	None	As above	1,197,793	171,883	2.24	171,883	
	Shih Her Technologies Inc.	None	As above	2,492,319	411,233	4.00	411,233	
	Drewloong Precision, Inc.	None	As above	1,773,333	247,380	4.43	247,380	
	UMS Integration Limited	None	As above	7,875,000	300,762	0.89	300,762	
	Beneficiaries certificates							
	Yuanta Japan Leading Enterprise Fund	None	Financial assets at FVTPL - current	53,614,369	266,647	-	266,647	
Yi Sheng Co., Ltd.	Listed stocks							
	Intai Technology Corp.	None	Financial assets at FVTOCI - current	2,330,000	237,660	4.60	237,660	
	Global PMX Co., Ltd.	None	As above	2,110,000	272,190	1.83	272,190	
	Highlight Tech Corp.	None	As above	1,330,400	63,061	1.41	63,061	
	Feedback Technology Corp.	None	As above	1,983,002	284,561	3.71	284,561	
	Shih Her Technologies Inc.	None	As above	1,650,812	272,382	2.65	272,382	
	Drewloong Precision, Inc.	None	As above	1,652,307	230,497	4.13	230,497	
	UMS Integration Limited	None	As above	13,250,000	506,044	1.49	506,044	
	Beneficiaries certificates							
	Yuanta Japan Leading Enterprise Fund	None	Financial assets at FVTPL - current	53,614,369	266,647	-	266,647	
Yi Fa Co., Ltd.	Listed stocks							
	Intai Technology Corp.	None	Financial assets at FVTOCI - current	2,396,000	244,391	4.73	244,391	
	Global PMX Co., Ltd.	None	As above	862,000	111,198	0.75	111,198	
	Highlight Tech Corp.	None	As above	388,000	18,391	0.41	18,391	
	Feedback Technology Corp.	None	As above	765,000	109,778	1.43	109,778	
	Drewloong Precision, Inc.	None	As above	1,248,589	174,178	3.12	174,178	
	Shih Her Technologies Inc.	None	As above	583,902	96,344	0.94	96,344	
Yi Chuan Co., Ltd.	Listed stocks							
	Global PMX Co., Ltd.	None	Financial assets at FVTOCI - current	533,000	68,757	0.46	68,757	
	Highlight Tech Corp.	None	As above	1,466,000	69,488	1.55	69,488	
	Drewloong Precision, Inc.	None	As above	1,908,717	266,266	4.77	266,266	
	Shih Her Technologies Inc.	None	As above	627,910	103,605	1.01	103,605	
Catcher Medtech Co., Ltd.	Listed stocks							
	Intai Technology Corp.	None	Financial assets at FVTOCI - current	2,185,000	222,870	4.31	222,870	
	Global PMX Co., Ltd.	None	As above	1,654,000	213,366	1.44	213,366	
Nanomag International Co., Ltd.	Limited partnerships							
	China Renewable Energy Fund, L.P.	None	Financial assets at FVTOCI - non-current	-	USD 50,169	23.51	USD 50,169	Note 3
	Listed stocks							
	UMS Integration Limited	None	Financial assets at FVTOCI - current	11,875,000	USD 14,175	1.34	USD 14,175	
	FUJIMI INCORPORATED	None	As above	918,400	USD 15,441	1.24	USD 15,441	
	MANI, INC.	None	As above	1,232,700	USD 12,642	1.36	USD 12,642	
	Corporate bonds							
	GOLDMAN SACHS INTERNATIONAL CALLABLE MEDIUM TERM NOTE FIXED	None	Financial assets at FVTOCI - non-current	20,000,000	USD 20,014		USD 20,014	
	Government bonds							
	US TREASURY	None	Financial assets at FVTOCI - non-current	2,687,000,000	USD 2,507,299		USD 2,507,299	
Cor Ventures Pte, Ltd.	Private equity funds							
	Ally Bridge Group LP	None	Financial assets at FVTPL - non-current	-	USD 14,406	2.54	USD 14,406	Note 3
	BPEA VIII	None	As above	-	USD 30,812	0.27	USD 30,812	Note 3
	Foreign listed shares							
	UMS Integration Limited	None	Financial assets at FVTOCI - non-current	12,437,500	USD 14,846	1.40	USD 14,846	

Note 1: Marketable securities in this table are shares, bonds, beneficiary certificates and those derived from the above-mentioned items which are within the scope of IFRS 9 “Financial Instrument: Recognition and Measurement”.

Note 2: Refer to Tables 6 and 7 for information on subsidiaries and associates.

Note 3: Percentage of ownership is the ratio of capital contribution.

Note 4: This table is prepared by the Company based on the principle of materiality to disclose marketable securities that are deemed necessary for listing.

Table 4

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

PURCHASES FROM OR SALES TO RELATED PARTIES AMOUNTING TO NT$100 MILLION OR MORE, OR 20% OR MORE OF THE PAID-IN CAPITAL
JANUARY 1 TO MARCH 31, 2026
(In Thousands of New Taiwan Dollars)

Buyer (Seller)	Transaction Counterparty	Relationship	Transaction Details				Reasons for Unusual Transactions		Notes and Accounts Receivable (Payable)		Note
			Purchase (sale)	Amount	% of total	Payment Terms	Unit Price	Payment Terms	Ending Balance	% of Total	
Catcher Technology Co., Ltd.	Next Level Ltd.	Subsidiary	Purchases	$ 1,484,597	81	Settled monthly; credit on 30-90 days	Equivalent	Equivalent	($ 1,898,113)	79	
Catcher Technology (Suqian) Co., Ltd.	Catcher Technology Co., Ltd.	Ultimate parent company	Sales	(150,725)	12	Settled monthly; credit on 30-90 days	Equivalent	Equivalent	313,071	9	
	Arcadia Technology (Suqian) Co., Ltd.	Same ultimate parent company	Sales	(949,008)	77	Settled monthly; credit on 30-90 days	Equivalent	Equivalent	3,043,995	83	
Vito Technology (Suqian) Co., Ltd.	Arcadia Technology (Suqian) Co., Ltd.	Same ultimate parent company	Sales	(189,094)	21	Settled monthly; credit on 30-90 days	Equivalent	Equivalent	219,122	16	
	Next Level Ltd.	Same ultimate parent company	Sales	(628,478)	69	Settled monthly; credit on 30-90 days	Equivalent	Equivalent	888,375	65	
Arcadia Technology (Suqian) Co., Ltd.	Next Level Ltd.	Same ultimate parent company	Sales	(838,115)	59	Settled monthly; credit on 30-90 days	Equivalent	Equivalent	968,932	54	

Table 5

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

RECEIVABLES FROM RELATED PARTIES AMOUNTING TO NT$100 MILLION OR MORE, OR 20% OR MORE OF THE PAID-IN CAPITAL
MARCH 31, 2026
(In Thousands of New Taiwan Dollars)

Company with Accounts Receivable	Transaction Counterparty	Relationship	Receivables from Related Parties Ending Balance	Turnover Rate (%)	Overdue		Amount Subsequently Recovered	Allowance for Doubtful Accounts
					Amount	Action Taken		
Catcher Technology Co., Ltd.	TOPO TECHNOLOGY (THAILAND) CO., LTD.	Subsidiary	$ 431,258	- (Note 2)	$ -	Not applicable	$ -	$ -
Catcher Technology (Suqian) Co., Ltd.	Vito Technology (Suqian) Co., Ltd.	Same ultimate parent company	272,582	- (Note 1)	-	Not applicable	71,568	-
	Vito Technology (Suqian) Co., Ltd.	As above	140,788	1.41	-	Not applicable	73,706	-
	Arcadia Technology (Suqian) Co., Ltd.	As above	3,043,995	1.14	-	Not applicable	683,021	-
	Envio Technology (Suqian) Co., Ltd.	As above	154,427	0.98	-	Not applicable	47,299	-
	Catcher Technology Co., Ltd.	Ultimate parent company	313,071	0.52	-	Not applicable	-	-
Vito Technology (Suqian) Co., Ltd.	Catcher Technology (Suqian) Co., Ltd.	Same ultimate parent company	189,328	1.95	-	Not applicable	33,613	-
	Arcadia Technology (Suqian) Co., Ltd.	As above	219,122	1.49	-	Not applicable	-	-
	Next Level Ltd.	As above	888,375	3.14	-	Not applicable	374,681	-
Arcadia Technology (Suqian) Co., Ltd.	Next Level Ltd.	Same ultimate parent company	968,932	2.38	-	Not applicable	842,149	-
Next Level Ltd.	Catcher Technology Co., Ltd.	Ultimate parent company	1,898,113	2.71	-	Not applicable	-	-

Note 1: These represent receivables arising from processing services; the turnover ratio is not applicable.

Note 2: Ending balance of loans, not applicable to turnover ratio calculation

Table 6

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

INFORMATION OF INVESTEES
JANUARY 1 TO MARCH 31, 2026
(In Thousands of New Taiwan Dollars, or Dollars for Other Foreign Currencies)

Investor Company	Investee Company	Locations	Main Businesses	Original Investment Amount		Investment Amount at the End of Period			Net Income (Loss) of the Investee	Investment Income (Loss) (Note 1)	Note
				End of the Current Period	End of Last Year	Number of Shares	Percentage %	Book Value			
The Company	Gigamag Co., Ltd.	Vistra Corporate Services Centre, Ground Floor NPF Building, Beach Road, Apia, Samoa	Investing activities	$ 484,941	$ 484,941	14,377,642	100	$ 2,137,402	$ 21,208	$ 21,208	
	Nanomag International Co., Ltd.	P.O. Box31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205 Cayman Islands	As above	1	1	30	100	156,721,650	1,082,854	1,082,122	
	Smart Ecare Inc.	13F, No. 99, Sec. 2, Dunhua S. Rd., Da'an District, Taipei City	Health and medical treatment consultant	72,000	72,000	1,440,000	45	3,673	37	17	
	Ke Yue Co., Ltd.	1F, No. 10, Lane 138, Ren'ai St, Yongkang District, Tainan City	Investing activities	4,322,980	4,322,980	211,619,800	100	4,911,746	28,407	28,407	
	Yi Sheng Co., Ltd.	1F, No. 10, Lane 138, Ren'ai St, Yongkang District, Tainan City	As above	2,649,919	2,649,919	89,770,000	100	3,279,587	21,322	21,322	
	Yi De Co., Ltd.	1F, No. 10, Lane 138, Ren'ai St, Yongkang District, Tainan City	As above	2,599,930	2,599,930	89,270,000	100	3,250,035	22,008	22,008	
	Catcher Medtech Co., Ltd.	No. 10, Yongke 5th Rd., Yongkang District, Tainan City	Manufacturing and selling medical devices	1,329,568	1,299,568	13,850,000	100	1,272,951	(18,884)	(18,891)	
	Catcher Holdings International Inc.	3524 Silverside Road Suite 35B, Wilmington, New Castle, United State	Investing activities	595,862 (USD 19,000,000)	45,129 (USD 1,500,000)	19,000,000	100	606,522	(1,046)	(1,046)	
	Yi Fa Co., Ltd.	1F, No. 10, Lane 138, Ren'ai St, Yongkang District, Tainan City	As above	2,500,000	2,500,000	25,180,000	100	2,616,658	16,606	16,606	
	Yi Chuan Co., Ltd.	1F, No. 10, Lane 138, Ren'ai St, Yongkang District, Tainan City	As above	2,500,000	2,500,000	25,180,000	100	2,528,113	9,428	9,428	
	Yi Zhu Co., Ltd.	1F, No. 10, Lane 138, Ren'ai St, Yongkang District, Tainan City	As above	252,000	252,000	25,180,000	100	258,334	788	788	
	Xincher Precision Manufacturing Co., Ltd.	House No.1 - Block A1 - Unit 6 - Lot CN5, Minh Duc Industrial Park, Ngoc Lam Ward, My Hao Town, Hung Yen Province	Manufacturing and selling varied alloy products	15,047	15,047	-	100	(5,548)	(3,226)	(3,885)	
	Topo Technology (Thailand) Co., Ltd.	700/2 Moo 1 Klongtamru sub-district, Muang district, Chonburi 20000, Thailand	Manufacturing and selling varied alloy products	478,250	478,250	4,999,998	100	484,481	(17,408)	(17,408)	
Ke Yue Co., Ltd.	Pacific Hospital Supply Co., Ltd.	No. 8, Tongke 2nd Rd., Jiuhu Village, Tongluo Township, Hsinchu Science Park, Miaoli County	Manufacturing and selling medical devices	567,523	567,523	7,563,000	10.42	729,334	104,468		
	Bioteque Corporation	5F-6, No. 23, Sec. 1, Chang'an East Rd., Zhongshan District, Taipei City 104	Biotechnology and medical industry	781,936	781,936	6,996,000	10.10	829,748	144,977		
	United Orthopedic Corporation	No. 57, Park Avenue 2, Hsinchu Science Park, Hsinchu City	Biotechnology and medical industry	393,635	393,635	4,774,000	4.95	445,438	87,796		
Yi Sheng Co., Ltd.	Pacific Hospital Supply Co., Ltd.	No. 8, Tongke 2nd Rd., Jiuhu Village, Tongluo Township, Hsinchu Science Park, Miaoli County	Manufacturing and selling medical devices	240,757	240,757	3,254,000	4.48	317,180	104,468		
	Bioteque Corporation	5F-6, No. 23, Sec. 1, Chang'an East Rd., Zhongshan District, Taipei City 104	Biotechnology and medical industry	279,319	279,319	2,591,000	3.74	308,036	144,977		
	United Orthopedic Corporation	No. 57, Park Avenue 2, Hsinchu Science Park, Hsinchu City	Biotechnology and medical industry	283,298	283,298	3,113,000	3.23	288,926	87,796		
Yi De Co., Ltd.	Pacific Hospital Supply Co., Ltd.	No. 8, Tongke 2nd Rd., Jiuhu Village, Tongluo Township, Hsinchu Science Park, Miaoli County	Manufacturing and selling medical devices	295,411	295,411	4,047,000	5.57	394,477	104,468		
	Bioteque Corporation	5F-6, No. 23, Sec. 1, Chang'an East Rd., Zhongshan District, Taipei City 104	Biotechnology and medical industry	245,534	245,534	2,252,000	3.25	267,705	144,977		
	United Orthopedic Corporation	No. 57, Park Avenue 2, Hsinchu Science Park, Hsinchu City	Biotechnology and medical industry	313,078	313,078	3,917,000	4.06	364,062	87,796		
Catcher Medtech Co., Ltd.	Pacific Hospital Supply Co., Ltd.	No. 8, Tongke 2nd Rd., Jiuhu Village, Tongluo Township, Hsinchu Science Park, Miaoli County	Manufacturing and selling medical devices	251,915	251,915	3,003,000	4.14	292,714	104,468		
	Bioteque Corporation	5F-6, No. 23, Sec. 1, Chang'an East Rd., Zhongshan District, Taipei City 104	Biotechnology and medical industry	290,840	290,840	2,729,000	3.94	304,035	144,977		
	Ren He Medtech Co., Ltd.	No. 10, Yongke 5th Rd., Yongkang District, Tainan City	Selling medical devices	2,000	2,000	200,000	100	1,928	(22)		
	Ren Yi Medtech Co., Ltd.	No. 10, Yongke 5th Rd., Yongkang District, Tainan City	Selling medical devices	2,000	2,000	200,000	100	1,928	(22)		
	COFORCE Medical Inc.	Address: 24F, No. 97, Sec. 2, Dunhua S. Rd., Da'an District, Taipei City	CDMO business for medical devices	220,000	220,000	22,000,000	100	137,894	(23,628)		
Yi Fa Co., Ltd.	Pacific Hospital Supply Co., Ltd.	No. 8, Tongke 2nd Rd., Jiuhu Village, Tongluo Township, Hsinchu Science Park, Miaoli County	Manufacturing and selling medical devices	553,240	553,240	6,134,000	8.45	543,278	104,468		
	Bioteque Corporation	5F-6, No. 23, Sec. 1, Chang'an East Rd., Zhongshan District, Taipei City 104	Biotechnology and medical industry	420,720	420,720	3,599,000	5.19	429,459	144,977		
	United Orthopedic Corporation	No. 57, Park Avenue 2, Hsinchu Science Park, Hsinchu City	Biotechnology and medical industry	882,682	882,682	9,231,000	9.57	855,238	87,796		
Yi Chuan Co., Ltd.	Pacific Hospital Supply Co., Ltd.	No. 8, Tongke 2nd Rd., Jiuhu Village, Tongluo Township, Hsinchu Science Park, Miaoli County	Manufacturing and selling medical devices	118,333	98,065	1,344,000	1.85	55,931	104,468		
	Bioteque Corporation	5F-6, No. 23, Sec. 1, Chang'an East Rd., Zhongshan District, Taipei City 104	Biotechnology and medical industry	167,455	146,288	1,408,000	2.03	171,427	144,977		
	United Orthopedic Corporation	No. 57, Park Avenue 2, Hsinchu Science Park, Hsinchu City	Biotechnology and medical industry	492,603	405,996	4,861,000	5.04	496,646	87,796		
Nanomag International Co., Ltd.	Stella International Co., Ltd.	P.O. Box31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205 Cayman Islands	As above	893,725 (USD 32,079,144)	893,725 (USD 32,079,144)	32,079,144	100	4,745,659	94,461		
	Uranus International Co., Ltd.	Room 1907, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong	As above	560,209 (USD 20,108,016)	560,209 (USD 20,108,016)	20,108,016	100	10,536,485	(51,134)		
	Norma International Co., Ltd.	Room 1907, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong	As above	530,247 (USD 19,032,525)	530,247 (USD 19,032,525)	19,032,525	100	4,403,657	(29,562)		
	Next Level Ltd.	Vistra Corporate Services Centre, Ground Floor NPF Building, Beach Road, Apia, Samoa	As above	279 (USD 10,000)	279 (USD 10,000)	10,000	100	615,941	10,283		
	Cor Ventures Pte. Ltd.	160 Robinson Road, #14-04 Singapore Business Federation Centre, Singapore 068914	As above	4,816,444 (USD 130,165,797)	4,816,444 (USD 130,165,797)	130,165,797	100	4,548,838	(96,994)		
Stella International Co., Ltd.	Lyra International Co., Ltd.	Room 1907, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong	Investing activities	- (USD 0)	- (USD 0)	-	100	-	-		
Catcher Holdings International Inc.	Catcher Ventures Inc.	14451 Chambers Road Suite 100 Tustin, CA 92780, United State	Investing activities	45,732 (USD 1,500,000)	45,732 (USD 1,500,000)	1,500,000	100	46,637	(1,018)		
	Niche Biomedical Inc.	10940 Wilshire Blvd., Suite 2030 Los Angeles, CA 90024 USA	Biotechnology and medical industry	314,450 (USD 10,000,000)	- (USD 0)	7,421,150	12.76	319,950	(49,867)		

Note 1: Disclose only investment income (loss) from directly owned subsidiaries and the investees accounted for using the equity method.

Note 2: Refer to Table 7 for the information on investment in Mainland China.

<u>**Table 7**</u>

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

INFORMATION ON INVESTMENTS IN MAINLAND CHINA
JANUARY 1 TO MARCH 31, 2026
(In Thousands of New Taiwan Dollars, or Dollars for Other Foreign Currencies)

Name of Investee in Mainland China	Main Businesses	Paid-in Capital (Note 13)	Method of Investment (Note 1)	Accumulated Investment Amount Remitted from Taiwan at the Beginning of the Current Period (Note 13)	Remittance of Funds		Accumulated Investment Amount Remitted from Taiwan at the End of the Current Period (Note 13)	Net Income (Loss) of the Investee	% Ownership of Direct or Indirect Investment	Recognized Investment Gains (Losses) for the Period (Note 2)	Book Value at the End of the Period	Repatriation of Investment Income as of the Current Period
					Outward	Inward						
Catcher Technology (Suzhou) Co., Ltd.	Manufacturing, selling and developing varied alloy products	$ -	(2) Cygnus International Co., Ltd. (Note 8)	$ 1,066,713 (USD 33,340,000)	$ -	$ -	$ 1,066,713 (USD 33,340,000)	$ -	-	$ -	$ -	$ -
Topo Technology (Suzhou) Co., Ltd.	As above	-	(2) Lyra International Co., Ltd. (Notes 4 and 5)	1,290,678 (USD 40,340,000)	-	-	1,290,678 (USD 40,340,000)	-	-	-	-	930,304
Topo Technology (Taizhou) Co., Ltd.	As above	-	(2) Lyra International Co., Ltd. (Note 9)	-	-	-	-	-	-	-	-	18,644,177
Meeca Technology (Taizhou) Co., Ltd.	As above	-	(2) Lyra International Co., Ltd. (Note 12)	-	-	-	-	-	-	-	-	4,777,580
Meeca Technology (Suzhou Industrial Park) Co., Ltd.	As above	-	(2) Cygnus International Co., Ltd. (Note 6)	-	-	-	-	-	-	-	-	2,109,621
Catcher Technology (Suqian) Co., Ltd.	As above	319,950 (USD 10,000,000)	(2) Uranus International Co., Ltd. (Note 7)	3,039,493 (USD 94,999,000)	-	-	3,039,493 (USD 94,999,000)	(5,473)	100	(6,470) (2)A.	6,667,556	10,801,111
Vito Technology (Suqian) Co., Ltd.	As above	319,950 (USD 10,000,000)	(2) Uranus International Co., Ltd. (Note 10)	-	-	-	-	(44,764)	100	(44,664) (2)A.	3,975,645	603,460
Arcadia Technology (Suqian) Co., Ltd.	As above	319,950 (USD 10,000,000)	(2) Norma International Co., Ltd. (Note 11)	-	-	-	-	4,686	100	(13,933) (2)A.	3,858,012	6,250,159
Envio Technology (Suqian) Co., Ltd.	As above	319,950 (USD 10,000,000)	(2) Norma International Co., Ltd. (Note 16)	-	-	-	-	(13,408)	100	(15,628) (2)A.	485,377	184,042
Aquila Technology (Suqian) Co., Ltd. (Note 17)	Manufacturing and selling varied molds and electronic components	-	(2) Cepheus International Co., Ltd.	35,834 (USD 1,120,000)	-	-	35,834 (USD 1,120,000)	-	-	-	-	169,684
WIT Technology (Taizhou) Co., Ltd. (Note 14)	Researching, developing and manufacturing electronic components	-	(2) Cetus International Co., Ltd.	-	-	-	-	-	-	-	-	-
Chaohu Yunhai Magnesium Co., Ltd. (Note 15)	Manufacturing and selling dolomite, aluminum, magnesium alloy and other alkaline-earth metals	-	(2) Sagitta International Co., Ltd.	706,511 (USD 22,081,923)	-	-	706,511 (USD 22,081,923)	-	-	-	-	-

Accumulated Investment Amount Remitted from Taiwan to Mainland China at the End of the Current Period (Note 13)	Investment Amounts Authorized by the Investment Commission, MOEA (Notes 13 and 14)	Upper Limit on the Amount of Investment in Mainland China Stipulated by the Investment Commission, MOEA (Note 3)
$ 6,139,230 (USD 191,880,923)	$ 47,143,843 (USD 1,091,748,726.39) (RMB 2,641,316,560.48)	$ 85,534,154

Note 1: The methods of investment include:
(1) Direct investment in Mainland China.
(2) Indirect investment in Mainland China through a company in a third region (please indicate the investing company in the third region)
(3) Other methods.

Note 2: Investment income (loss) shall be:
(1) Specified if the investee is in the preparation stage with no investment income (loss) incurred.
(2) Specified based on the following three principles of recognition:
A. The financial statements reviewed by global accounting firms affiliated with the accounting firms in Taiwan.
B. The financial statements reviewed by the CPAs of the parent company in Taiwan.
C. Others.

Note 3: The upper limit on investment in Mainland China is calculated as: $142,556,924 × 60% = $85,534,154

Note 4: The paid-in capital of US$6,670,000, which was self-owned funds of Nanomag International Co., Ltd., was then invested in Topo Technology (Suzhou) Co., Ltd. via Stella International Co., Ltd. The investee thereafter raised its capital by US$33,300,000 out of earnings in the third quarter of 2011 and returned US$33,300,000 via capital reduction in the fourth quarter of 2014.

Note 5: The paid-in capital of US$30,000,000, which was the earnings distributed by Topo Technology (Suzhou) Co., Ltd. to Stella International Co., Ltd., was then invested in Topo Technology (Suzhou) Co., Ltd., with the amount of US$67,000,000 returned via capital reduction in the first quarter of 2016. Lyra International Co., Ltd. sold all of its equity in November 2021; the proceeds have not yet been remitted back to Taiwan and therefore have not been deducted from the investment amount authorized by the Investment Commission, MOEA.

Note 6: The paid-in capital of US$106,000,000, which was the earnings distributed by Catcher Technology (Suzhou) Co., Ltd. to Castmate International Co., Ltd., was then invested in Meeca Technology (Suzhou Industrial Park) Co., Ltd., with capital increase of US$16,670,000 out of earnings in the third quarter of 2011. The amount of US$16,670,000 was returned via capital reduction in the fourth quarter of 2014 and the amount of US$32,000,000 in the third quarter of 2016. Thereafter, the amount of US$32,000,000 was returned via capital reduction in the second quarter of 2017, and the amount of US$32,000,000 was returned via capital reduction in the third quarter of 2017. Cygnus International Co., Ltd. sold all of its equity in November 2021; the proceeds have not yet been remitted back to Taiwan and therefore have not been deducted from the investment amount authorized by the Investment Commission, MOEA.

Note 7: The paid-in capital of US$5,001,000, which was the earnings distributed by Catcher Technology (Suzhou) Co., Ltd. to Castmate International Co., Ltd., was then invested in Catcher Technology (Suqian) Co., Ltd. The amount of US$100,000,000, which was the earnings distributed by Topo Technology (Suzhou) Co., Ltd. to Stella International Co., Ltd., was reinvested in Catcher Technology (Suqian) Co., Ltd. via Uranus International Co., Ltd. This amount was returned as a capital reduction of US$100,000,000 in May 2024, but the investment funds have not yet been remitted back to Taiwan. Therefore, this amount has not yet been deducted from the approved investment amount by the Ministry of Economic Affairs. US$ 50,000,000 was returned in September 2024 due to capital reduction, but has not been remitted back to Taiwan and therefore has not been deducted from the investment amount authorized by the Investment Commission, MOEA. US$ 35,000,000 was returned in May 2025 due to capital reduction, but has not been remitted back to Taiwan and therefore has not been deducted from the investment amount authorized by the Investment Commission, MOEA. US$ 5,000,000 was returned in November 2025 due to capital reduction, but has not been remitted back to Taiwan and therefore has not been deducted from the investment amount authorized by the Investment Commission, MOEA.

Note 8: The paid-in capital of US$16,670,000 was from earnings distributed in the third quarter of 2011 and US$40,000,000 was returned through capital reduction in the second quarter of 2014. An additional US$10,010,000 was returned in August 2016 upon liquidation. However, the investment funds have not yet been remitted back to Taiwan and, therefore, have not yet been deducted from the investment amount approved by the Investment Commission, MOEA.

Note 9: The paid-in capital of RMB227,510,746, which was the earnings distributed by Topo Technology (Suzhou) Co., Ltd. to Stella International Co., Ltd., was then invested in Topo Technology (Taizhou) Co., Ltd. The paid-in capital of US$65,979,240 and RMB602,268,326, which were the earnings distributed by subsidiaries in Mainland China to Nanomag International Co., Ltd., were then invested in Topo Technology (Taizhou) Co., Ltd. via Lyra International Co., Ltd. Lyra International Co., Ltd. sold all of its equity in December 2020; the proceeds have not yet been remitted back to Taiwan and therefore have not been deducted from the investment amount authorized by the Investment Commission, MOEA.

Note 10: The paid-in capital of US$99,000,000, which was the earnings distributed by Catcher Technology (Suzhou) Co., Ltd. to Nanomag International Co., Ltd., was then invested in Vito Technology (Suqian) Co., Ltd. via Uranus International Co., Ltd. The paid-in capital of US$33,300,000 and RMB409,431,280, which were the earnings respectively distributed by Topo Technology (Suzhou) Co., Ltd. to Nanomag International Co., Ltd., were then invested in Vito Technology (Suqian) Co., Ltd. via Uranus International Co., Ltd. US$ 48,901,367 was returned in February 2025 due to capital reduction, but has not been remitted back to Taiwan and therefore has not been deducted from the investment amount authorized by the Investment Commission, MOEA. US$ 35,000,000 was returned in May 2025 due to capital reduction, but has not been remitted back to Taiwan and therefore has not been deducted from the investment amount authorized by the Investment Commission, MOEA. US$ 5,000,000 was returned in November 2025 due to capital reduction, but has not been remitted back to Taiwan and therefore has not been deducted from the investment amount authorized by the Investment Commission, MOEA.

Note 11: The paid-in capital of US$27,332,360 and RMB398,499,193, which were the earnings respectively distributed by Catcher Technology (Suzhou) Co., Ltd. and Topo Technology (Suzhou) Co., Ltd. to Nanomag International Co., Ltd., were then invested in Arcadia Technology (Suqian) Co., Ltd. via Norma International Co., Ltd. The paid-in capital of US$89,970,000, which was the proceeds from the capital reduction of Catcher Technology (Suzhou) Co., Ltd., Topo Technology (Suzhou) Co., Ltd., and Meeca Technology (Suzhou Industrial Park) Co., Ltd., was then invested in Arcadia Technology (Suqian) Co., Ltd. via Norma International Co., Ltd. The paid-in capital of US$21,501,167, which was the earning distributed by Catcher Technology (Suzhou) Co., Ltd. and Topo Technology (Suzhou) Co., Ltd. to Nanomag International Co., Ltd., was then invested in Arcadia Technology (Suqian) Co., Ltd. via Norma International Co., Ltd. US$ 160,501,166 was returned in February 2025 due to capital reduction, but has not been remitted back to Taiwan and therefore has not been deducted from the investment amount authorized by the Investment Commission, MOEA. US$ 30,000,000 was returned in November 2025 due to capital reduction, but has not been remitted back to Taiwan and therefore has not been deducted from the investment amount authorized by the Investment Commission, MOEA.

Note 12: The paid-in capital of US$17,610,861 and RMB529,989,796, which were the earnings distributed by Catcher Technology (Suzhou) Co., Ltd. and Topo Technology (Suzhou) Co., Ltd. to Nanomag International Co., Ltd., were then invested in Meeca Technology (Taizhou) Co., Ltd. via Lyra International Co., Ltd. The paid-in capital of US$20,000,000 and RMB284,660,400, which were the earnings and liquidation income distributed by Catcher Technology (Suzhou) Co., Ltd. and earnings distributed by Topo Technology (Suzhou) Co., Ltd. and Meeca Technology (Suzhou Industrial Park) Co., Ltd. to Nanomag International Co., Ltd., were then invested in Meeca Technology (Taizhou) Co., Ltd. via Lyra International Co., Ltd. The paid-in capital of US$18,000,000, which was the earning distributed by Lyra International Co., Ltd. to Topo Technology (Taizhou) Co., Ltd., was invested in Meeca Technology (Taizhou) Co., Ltd. Lyra International Co., Ltd. sold all of its equity in December 2020; the proceeds have not yet been remitted back to Taiwan and therefore have not been deducted from the investment amount authorized by the Investment Commission, MOEA.

Note 13: Calculated based on the USD to NTD exchange rate of 31.995 as at the end of period.
Calculated based on the RMB to NTD exchange rate of 4.62396 as at the end of period.

Note 14: WIT Technology (Taizhou) Co., Ltd. was dissolved in June 2012; the remaining share capital has not yet been remitted back to Taiwan and therefore has not been deducted from the investment amount authorized by the Investment Commission, MOEA.

Note 15: Sagitta International Co., Ltd. sold all of its shares of Chaohu Yunhai Magnesium Co., Ltd. in June 2016, but has not remitted the proceeds back to Taiwan. The investment thus has not been deducted from the investment amount authorized by the Investment Commission, MOEA.

Note 16: The paid-in capital of US$71,010,000 and RMB188,956,820, which were the returned capital resulting from liquidating Catcher Technology (Suzhou) Co., Ltd. and the returned capital resulting from the capital reduction of Topo Technology (Suzhou) Co., Ltd. and Meeca Technology (Suzhou Industrial Park) Co., Ltd., were reinvested in Envio Technology (Suqian) Co., Ltd. through Norma International Co., Ltd. US$ 50,000,000 was returned in September 2024 due to capital reduction. However, the investment funds have not yet been remitted back to Taiwan and, therefore, have not yet been deducted from the investment amount approved by the Investment Commission, MOEA. US$ 30,000,000 was returned in February 2025 due to capital reduction, but has not been remitted back to Taiwan and therefore has not been deducted from the investment amount authorized by the Investment Commission, MOEA. US$ 10,000,000 was returned in November 2025 due to capital reduction, but has not been remitted back to Taiwan and therefore has not been deducted from the investment amount authorized by the Investment Commission, MOEA.

Note 17: Aquila Technology (Suqian) Co., Ltd. was dissolved in February 2022; the proceeds have not been remitted back to Taiwan and therefore have not been deducted from the investment amount authorized by the Investment Commission, MOEA.

Table 8

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT TRANSACTIONS

JANUARY 1 TO MARCH 31, 2026

(In Thousands of New Taiwan Dollars)

No.	Company name	Counterparty of intercompany transactions	Relationship with transaction party (Note 1)	Transaction details			
				Account	Amount (Note 2)	Trading terms	Percentage of consolidated total revenue or total assets %
0	Catcher Technology Co., Ltd.	TOPO TECHNOLOGY (THAILAND) CO., LTD.	1	Other receivables from related parties (loaning of funds)	$ 431,258		0.19
		Next Level Ltd.	1	Payables to related parties	1,898,113		0.84
				Purchases	1,484,597	Calculated based on general transaction prices; settled monthly; payment on 30-90 days	39.34
1	Catcher Technology (Suqian) Co., Ltd.	Catcher Technology Co., Ltd.	2	Receivables from related parties	313,071		0.14
				Sales revenue	150,725	Calculated based on general transaction prices; settled monthly; credit on 30-90 days	3.99
		Vito Technology (Suqian) Co., Ltd.	3	Receivables from related parties	140,788		0.06
				Other receivables from related parties	272,582		0.12
				Processing income	113,546	Calculated based on general transaction prices; settled monthly; credit on 30-90 days	3.01
				Payables to related parties	125,945		0.06
				Other payables - related parties	86,975		0.04
		Arcadia Technology (Suqian) Co., Ltd.	3	Receivables from related parties	3,043,995		1.35
				Payables to related parties	75,551		0.03
				Sales revenue	949,008	Calculated based on general transaction prices; settled monthly; credit on 30-90 days	25.15
		Envio Technology (Suqian) Co., Ltd.	3	Receivables from related parties	154,427		0.07
				Other receivables from related parties (loaning of funds)	64,736		0.03
2	Vito Technology (Suqian) Co., Ltd.	Catcher Technology (Suqian) Co., Ltd.	3	Receivables from related parties	189,328		0.08
				Sales revenue	78,526	Calculated based on general transaction prices; settled monthly; credit on 30-90 days	2.08
		Arcadia Technology (Suqian) Co., Ltd.	3	Receivables from related parties	219,122		0.10
				Payables to related parties	99,565		0.04
				Sales revenue	189,094	Calculated based on general transaction prices; settled monthly; credit on 30-90 days	5.01
		Xincher Precision Manufacturing Co., Ltd.	3	Receivables from related parties	53,214		0.02
		Next Level Ltd.	3	Receivables from related parties	888,375		0.39
				Sales revenue	628,478	Calculated based on general transaction prices; settled monthly; credit on 30-90 days	16.65
3	Arcadia Technology (Suqian) Co., Ltd.	Next Level Ltd.	3	Receivables from related parties	968,932		0.43
				Sales revenue	838,115	Calculated based on general transaction prices; settled monthly; credit on 30-90 days	22.21
4	Catcher Medtech Co., Ltd.	COFORCE Medical Inc.	3	Other receivables from related parties (loaning of funds)	70,000		0.03

Note 1: The relationships with the transaction counterparty include:

1. Transactions from the parent company to subsidiaries.
2. Transactions from subsidiaries to the parent company.
3. Transactions between subsidiaries.

Note 2: Written off at the time of preparing the consolidated financial report.

Table 9

CATCHER TECHNOLOGY CO., LTD. AND SUBSIDIARIES

STATEMENT OF CHANGES IN PROPERTY, PLANT AND EQUIPMENT
JANUARY 1 TO MARCH 31, 2026 AND 2025
(In Thousands of New Taiwan Dollars)

	Land	Buildings	Machinery and Equipment	Miscellaneous Equipment	Unfinished Construction and Equipment Pending Acceptance	Total
Costs						
Balance at January 1, 2025	$ 1,998,517	$ 16,743,149	$ 45,804,011	$ 6,732,462	$ -	$ 71,278,139
Addition	-	7,496	32,481	50,334	-	90,311
Disposal	-	(701)	(939,582)	(29,741)	-	(970,024)
Reclassification	-	7,506	98,235	684	-	106,425
Acquisition through business combination (Note 29)	462,244	2,259,686	259,155	63,874	-	3,044,959
Effect of foreign currency exchange difference	-	193,062	236,152	64,411	-	493,625
Balance at March 31, 2025	$ 2,460,761	$ 19,210,198	$ 45,490,452	$ 6,882,024	$ -	$ 74,043,435
Accumulated depreciation and impairment						
Balance at January 1, 2025	$ -	$ 8,773,723	$ 44,123,733	$ 6,520,240	$ -	$ 59,417,696
Depreciation expense	-	184,362	142,136	50,801	-	377,299
Disposal	-	(336)	(932,981)	(28,997)	-	(962,314)
Effect of foreign currency exchange difference	-	113,396	215,533	61,712	-	390,641
Balance at March 31, 2025	$ -	$ 9,071,145	$ 43,548,421	$ 6,603,756	$ -	$ 59,223,322
Net amount at March 31, 2025	$ 2,460,761	$ 10,139,053	$ 1,942,031	$ 278,268	$ -	$ 14,820,113
Costs						
Balance at January 1, 2026	$ 2,580,306	$ 18,845,709	$ 43,447,839	$ 6,866,743	$ 1,286	$ 71,741,883
Addition	-	3,391	168,838	58,485	52	230,766
Disposal	-	-	(325,586)	(3,295)	-	(328,881)
Reclassification	-	-	11,000	5,547	-	16,547
Effect of foreign currency exchange difference	-	452,829	972,205	161,052	-	1,586,086
Balance at March 31, 2026	$ 2,580,306	$ 19,301,929	$ 44,274,296	$ 7,088,532	$ 1,338	$ 73,246,401
Accumulated depreciation and impairment						
Balance at January 1, 2026	$ -	$ 9,346,753	$ 41,629,262	$ 6,578,718	$ -	$ 57,554,733
Depreciation expense	-	182,364	137,440	46,290	-	366,094
Disposal	-	-	(325,572)	(3,281)	-	(328,853)
Effect of foreign currency exchange difference	-	283,461	937,982	158,293	-	1,379,736
Balance at March 31, 2026	$ -	$ 9,812,578	$ 42,379,112	$ 6,780,020	$ -	$ 58,971,710
Net amount as of December 31, 2025 and January 1, 2026	$ 2,580,306	$ 9,498,956	$ 1,818,577	$ 288,025	$ 1,286	$ 14,187,150
Net amount as of March 31, 2026	$ 2,580,306	$ 9,489,351	$ 1,895,184	$ 308,512	$ 1,338	$ 14,274,691